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ABSTRACT 
Background 
Nigeria accounted for 2.95 million of the 22 million people globally living with 
HIV in 2008. In 2010, the HIV prevalence increased to 3.1 million, with 1.5 
million people requiring anti-retroviral treatment (ART). ART is effective if 
patients adhere to treatment (taking 95% or more of drugs as prescribed) over a 
sustained period. Taking less than 95% of the medication can lead to drug 
resistance and treatment failure, which have dire individual and public health 
consequences. This study described adherence to ART and the factors that 
constrain and motivate adherence among patients on ART at the University of 
Abuja Teaching Hospital in the Federal Capital Territory (FCT), Nigeria.  
Methodology 
An observational, descriptive and analytical, cross-sectional survey of adherence 
among 502 adult ART patients (254 women and 248 men) from the University of 
Abuja Teaching Hospital was conducted. I collected sociodemographic and 
clinical characteristics of participants, and barriers and facilitators to adherence. 
For the prescription refill data, I utilized the updated pharmacy refill records from 
the ART dispensary. Bivariate and multivariate analysis was performed to 
analyse the factors that influence adherence to ART. 
Results 
Participants in this study had been on therapy for a mean of 43±27 months. Total 
optimal self-reported adherence over the previous three days (not missing a dose, 
taking correct doses in the correct frequency and correct schedule) was 53.6%, 
compared with 62.5% adherence calculated by prescription refill. However, most 
(80.3%) participants achieved virologic suppression at a level of <400 copies/µl
3
. 
Reported barriers to adherence were: forgot (43%); travelled away from home 
(21%); ran out of medication (16%); busy at work (13%); lack of food (5%) and 
medication snatched by armed robbers (2%). Self-reported adherence over the 
previous three days was positively associated with age and viral load. Younger 
respondents (under 30 years) were 3 times more likely to adhere to their regimen 
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compared with those older than 30 years (OR = 2.5; 95% CI = 1.26-4.61; p = 
0.023). As expected, participants who had adequate viral suppression ( <400 
copies/µl
3
)
 
were 7 times more likely to report optimal total adherence to their 
medications over the previous three days  compared to those who did not have 
adequate viral suppression (>400 copies/µl
3
)
 
(OR = 6.6; 95% CI = 1.6- 11.07).  
Conclusion 
Most participants (above 90%) continued on ART and majority (80.3%) achieved 
satisfactory viral suppression. However, 53.6% had suboptimal adherence to ART 
because participants were not taking their medications as prescribed. Strategies to 
address adherence to ART must emphasize taking medication at the correct times 
and on schedule. 
 
 
 
 
  
 
 
 
 
v | P a g e  
 
DECLARATION 
I declare that Adherence to antiretroviral therapy in the Federal Capital Territory, 
Abuja, Nigeria is my own work, that it has not been submitted before for any degree or 
examination in any University or College, and that all the sources I have quoted or used have 
been indicated and acknowledged as complete references. 
 
 
Yohanna K. Avong                                                                                 24 August 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi | P a g e  
 
 
                                                     DISCLAIMER 
This publication was made possible by UMB AITRIP Grant Number 5-D43 TWO 10441 from 
the United States’ National Institutes of Health’s Forgarty International Center awarded to Dr. 
William Blattner of the Institute of Human Virology, University of Maryland, Baltimore. Its 
content are solely the responsibility of the authors and do not necessarily represent the official 
views of the awarding office of the NIH/Forgarty International Center. 
 
 
 
 
 
 
 
 
                                                           
  
 
 
 
 
vii | P a g e  
 
ACRONYMS 
AIDS: Acquired Immunodeficiency Syndrome 
ART: Antiretroviral Therapy 
ARV: Antiretroviral 
ACTION:  AIDS Care and Treatment in Nigeria  
HAART: Highly Active Antiretroviral Therapy 
HIV: Human Immunodeficiency Virus 
CD4: Cluster of Differentiation at level 4 
FMOH: Federal Ministry of Health 
PLWHA: People Living with HIV and AIDS 
PEPFAR: United States Presidential Emergency Plan for AIDS Relief 
IHVN: Institute of Human Virology, Nigeria 
STI: Sexual Transmitted Infections 
WHO: World Health Organization 
 
 
 
 
                               
 
 
 
 
viii | P a g e  
 
ACKNOWLEDGEMENT 
It is very easy to appreciate people that have done you a favor with a “thank you”.  It is not 
that easy when you have to appreciate people who put down their lives, sacrifice their time 
and went the Biblical “extra mile” to ensure that you have succeeded in your work. You will 
not have the word to appreciate them – this is the difficulty I have appreciating the 
innumerable number of people that contributed to this work.  
 
My supervisor, Dr. Brian Van Wyk, did more than what is required from a supervisor of a 
thesis. He was a mentor, a teacher and if this work were a football/soccer match, he was my 
Coach and the Referee at the same time. He ensured that I won the match but without 
“fixing” the result of the match. Young upcoming African researchers would undoubtedly 
benefit from the vast knowledge of Brian.  I pray God will sustain him with long life for the 
youths of Africa. 
The management of the Institute of Human Virology, University of Maryland, Baltimore 
(UMD), USA and the Institute of Human Virology, Nigeria (IHVN) provided moral, 
financial and all the support I needed to do this work. Professor William Blattner – the 
“father of all nations” - through the Forgarty AITRP provided the financial support for this 
work. Blattner is deeply concerned about adherence to antiretroviral therapy, having been the 
pioneer principal investigator (PI) and implementer of the PEPFAR/ACTION project in 
Nigeria. I hope he will find the findings of this study interesting. Dr. Patrick Sunday Dakum 
– the chief executive officer (CEO) of the Institute of Human Virology, Nigeria and the “Ngu 
Man-dak Mupun” of the Mupun Kingdom, Plateau State, Nigeria - was my source of 
encouragement for this work. Dr. Dakum has the wonderful gift of wisdom bestowed on him 
by God; he is never confused on issues but always has the right word for the moment. His 
 
 
 
 
ix | P a g e  
 
wisdom undoubtedly helped me overcame some of the challenges I encountered in the course 
of this work. But most importantly, Dakum has devoted the most productive phase of his life 
to public health and this inspired me to read a Master’s degree in Public Health. Professor 
Clement Adebamawo – Director, Office of Strategic Information, Training and Research, 
facilitated the financial support I received for the work. Dr Alashile Abimiku – Co-Principal 
Investigator and Senior Technical Advisor, Clinical Laboratory Services, gave me the works 
of Professor Robert Gallo (co-discoverer of HIV-1) and the work she did in Nigeria – “HIV 
Subtype and Drug Resistance Pattern among Drug Naïve Persons in Jos, Nigeria”. Through 
these works, I understood the human immunodeficiency virus (HIV) better and insisted on 
conducting the viral load tests. Dr. Gabou Mendy has so many things to learn from. It is from 
him I learnt the dictum: “I’m so far behind I thought I was first”. Dr. Charles Mensah is many 
things – Director of Project, Deputy Chief of Party, etc. But I prefer addressing him simply as 
“Mr. Charles,” because he is truly a “Master” in anything he is involved with. Once, he told 
me “do not play with this study”. Since then, I took the study very serious. 
 
There are many other people outside the management of IHVN that made invaluable 
contributions to this work. The lab “guys” – Richard Enzama (the High Priest of Uganda), 
Mrs Ndidi Agala, Ibrahim Baba Dafa, and Dr. Sam Peters performed wonders. They designed 
the protocols for the viral load test, ordered for reagents, supervised the blood collection and 
performed the viral assay. I will never forget how Mrs. Agala stood in the Abuja scorching 
sun for over 6 hours assisting me pull out my car from a deep gully. We ran into the gully in 
an attempt to cut off a debilitating traffic jam on our way to Gwagwalada for data collection. 
Rachael Adegbola (IHVN Epidemiologist) helped in the design of the exit questionnaires, 
Makwin Kuba (IHVN Statistician) assisted with the data cleaning and Dr. Jean Njab 
(Principal Statistician at the Population Council), provided all the assistance required for the 
 
 
 
 
x | P a g e  
 
data analysis. He allowed me to visit him in the office and even at home when he should be 
resting with his family. Four wonderful pharmacists, Atsen Nyam, Fwanshak Guar, Ashega 
Kigbu and Ritmwa Gwan spend two and half months in the field collecting the data with me. 
We have become life time friends through this work. Professor Richard Laing, World Health 
Organization, Geneva and Dr. John Chalker – researcher and clinician, provided me with the 
first set of literatures on how to collect the data. They also allowed me to write them several 
times and not even once did they fail to respond to my mails. My colleagues in the office, Dr. 
Gebi Usman, Dennis Mordi, David Jonathan, Blessing Ukpabi (international journalist and 
“photographer”), Pharms Charity Omenka, Chika Ojinna and now, Hamzat Omotayo, Pharm 
Bola Obembe and Istifanus Sako provided fellowship and I appreciate them. 
 
A few organizations also contributed to the success of this work. I have already mentioned 
UMD and IHVN and now, the US Presidential Emergency Plan for AIDS Relief (PEPFAR) 
and the Centers for Disease Control (CDC), Nigeria. The University of Abuja Teaching 
Hospital approved the study within one month – some people said this was unusual 
considering the fact that human subjects were involved. Almost all the staff of the ART clinic 
assisted with the data collection; it is practically impossible to list all the names but Dr Oche 
Yusuf led the team. The University of the Western Cape (UWC), South Africa, gave me the 
admission and the opportunity to learn. With Nelson Mandela as the Chancellor of UWC for 
many years, it was simply an honor to be associated with this great institution. Mrs. Corinne 
Carolissen and Janine Kader in the administration department did what some people call the 
“dirty job”. They were the ones who were in direct contact with us the students; they suffered 
the insults any one will suffer dealing with stubborn students of whom I’m chief. But as great 
ladies, they tolerated us and whatever success the students may have achieved, the glory and 
the praise must go to these ladies and their colleagues in the department. 
 
 
 
 
xi | P a g e  
 
 
I wish my mother could still see; she would have been overwhelmed with joy seeing the 
beautiful MPH certificate. What should I do? I will place her frail hands on the certificate to 
appreciate her for rising every morning to cook my delicious “Tuck”. It was this local Kataf 
(Atyap) meal that gave me the strength to cross the river Wonderful and trek the long 
distance to my local primary school for six years. As for Dad, when I do join him in Heaven 
someday, I will show him the certificate and tell him, “I made it dad”. 
 
My immediate family – my wife (Eunice Bosede) who has always inspired me to study and 
our beautiful daughters – Nnaye, Glory and Heart were in the trenches with me. Perhaps, they 
suffered more pain than me in the course of this work. I truly appreciate them and I hope my 
daughters would be inspired by this work and shall one day do more than what I have done. 
I really hate flying because I hate airplane crashes. But none of the airplanes I used in all my 
trips to South Africa experienced serious turbulence. The LORD JESUS CHRIST, who holds 
all things by the word of HIS Power according to the Scripture (Hebrew 1: 3), provided safe 
air trips; He also gave me sound health and His Holy Spirit practically guided me as the 
“Spiritual Supervisor”. Since the LORD cannot accept anything other than a “thank you”, I 
say THANK YOU MY LORD. 
 
  
 
 
 
 
xii | P a g e  
 
TABLE OF CONTENTS 
 
TITLE…………………………………………………………………………………………..i
  
KEY WORD……………………………………………………………………………… ...... ii 
ABSTRACT………………………………………………………………………………. ..... iii 
DECLARATION…………………………………………………………………………........ v 
DISCLAIMER………………………………………………………………………….... ...... vi 
ACRONYMS……………………………………………………………………………. ...... vii 
ACKNOWLEDGEMENTS………………………………………………………………. ... viii 
TABLE OF CONTENTS………………………………………………………………... ...... xii 
LIST OF FIGURES…………………………………………………………………… ........ xvi 
LIST OF TABLES……………………………………………………………………. ......... xvi 
LIST OF APPENDICES…………………………………………………………….. .......... xvii 
CHAPTER ONE: INTRODUCTION………………………………………………….. ...... 1 
1.1 Background……………………………………………………………………………. ..... 1 
1.2 Country Profile………………………………………………………………………… ..... 1 
1.3 HIV/AIDS in Nigeria………………………………………………………………….. ..... 5 
1.4 The National Response to the HIV and AIDS in Nigeria…………………………….. ...... 7 
1.5 Problem Statement……………………………………………………………………... .... 9 
CHAPTER TWO: LITERATURE REVIEW………………………………………… ..... 10 
2.1 Introduction…………………………………………………………………………... ..... 10 
2.2 Definition of Concepts……………………………………………………………….. ..... 10 
2.3 Aherence to Combination Antiretroviral Therapy…………………………………… ..... 14 
 
 
 
 
xiii | P a g e  
 
2.4 Poor Adherence in Sub-Saharan Africa……………………………………………… ..... 16 
2.5 Poor Adherence in Nigeria………………………………………………………… ......... 17 
2.6 ART Failure………………………………………………………………………… ....... 19 
2.7 Measuring Adherence to ART……………………………………………………… ....... 19 
2.8 Factors that Affect Adherence to Combination ART……………………………… ........ 23 
2.8.1 Patient-level Factors………………………………………………………………. ..... 23 
2.8.2 Treatment Regimen Factors……………………………………………………… ..... 33 
2.8.3 Patient Provider Relationship Factors……………………………………………. .. 35 
2.8.4 Clinic Setting/Health Facility Factors……………………………………………. ... 37 
2.8.5 Diseases Characteristics Factors………………………………………………….. .. 39 
2.9 Study Designs and Methodologies in Previous Adherence Studies………………........... 40 
2.10 Adherence in Different Settings………………………………………………….. ......... 41 
2.11 Summary…………………………………………………………………………... ....... 42 
CHAPTER THREE: METHODOLOGY…………………………………………… ........ 44 
3.1 Aim of the Study…………………………………………………………………… ........ 44 
3.2 Objectives of the Study……………………………………………………………. ......... 44 
3.3 Study Setting………………………………………………………………………. ......... 44 
3.4 Study Design………………………………………………………………………. ......... 47 
3.5 Study Population and Sampling ………………………………………………...... .......... 47 
3.6 Data Collection………………………………………………………………….... .......... 50 
3.7 Data Management…………………………………………………………………. ......... 59 
3.8 Data Analysis……………………………………………………………………. ............ 59 
3.9 Validity………………………………………………………………………….. ............ 62 
 
 
 
 
xiv | P a g e  
 
3.10 Reliability……………………………………………………………………….. ........... 66 
3.11 Generalizability…………………………………………………………………. ........... 67 
3.12 Ethical Considerations………………………………………………………….. ........... 67 
CHAPTER FOUR: RESULTS…………………………………………………… ............. 68 
4.1 Introduction……………………………………………………………………… ............ 68 
4.2 Socio-demographic Characteristics of Participants……………………………… ........... 68 
4.3 Clnical Characteristics of Participants…………………………………………… ........... 71 
4.4 Behavioral Characteristics……………………………………………………….. ........... 72 
4.5 Adherence……………………………………………………………………… .............. 74 
4.6 Health System Factors…………………………………………………………… ........... 77 
4.7 Factors Associated with Adherence……………………………………………. .............. 80 
4.8 Summary………………………………………………………………………….. .......... 83 
CHAPTER FIVE: DISCUSSION………………………………………………….. ........... 84 
5.1 Introduction………………………………………………………………………. ........... 84 
5.2 Socio-demographic Characteristics of Adult ART Patients ……………………….......... 87 
5.3 Clinical Characteristics of Adult ART Patients…………………………. ........................ 87 
5.4 Health System Factors………………………………………………………… ............... 92 
5.5 Behavioural Characteristics………………………………………………………... ........ 96 
5.6 Adherence to the ART in the FCT………………………………………………… ......... 97 
5.7 Limitations of the Study…………………………………………………………… ....... 111 
5.8 Strengths of the Study…………………………………………………………….. ........ 114 
5.9 Summary…………………………………………………………………………… ...... 117 
CHAPTER SIX: CONCLUSION AND RECOMMENDATIONS……………… ......... 118 
 
 
 
 
xv | P a g e  
 
6.1 Conclusion………………………………………………………………………… ....... 118 
6.2 Recommendations for Improving Adherence to Highly Active Antiretroviral 
Therapy……………………………………………………………………………….. ........ 119 
 
REFERENCES………………………………………………………………………… ..... 124 
 
 
  
 
 
 
 
xvi | P a g e  
 
LIST OF FIGURES 
Figure 1.1 Map of Nigeria Showing the 36 States and the FCT in White Background……. ... 4 
Figure 2.1 Factors Leading to Poor Adherence to ART…………………………………….. 43 
Figure 3.1 A Cross Section of the University of Abuja Teaching Hospital, Gwagwalada, 
FCT………………………………………………………………………………………… .. 45 
Figure 3.2 An Interactive Session………………………………………………………….. . 49 
Figure 3.3 A Phlebotomist Taking Blood Sample from a Participants…………………….. . 56 
Figure 3.4 A PEPFAR Trained Medical Laboratory Scientist Performing Viral Assay……  . 57 
Figure 3.5 A Data Collector being Friendly during an Interview with a Participant………. . 64 
Figure 4.1 Recruitment of Participants of the Study……………………………………….. . 68 
Figure 4.2 Targets of HIV Disclosure………………………………………………………. 74 
Figure 4.3 Reasons for Missing Doses……………………………………………………… 76 
Figure 4.4 Reasons for Not Missing Doses………………………………………………..... 77 
Figure 4.5 Distance Travelled to the ART Clinic………………………………………….... 78 
Figure 4.6 Travel Cost to the ART Clinic………………………………………………….... 79 
Figure 4.7 Time Spent in the ART Clinic………………………………………………….... 80 
 
LIST OF TABLES 
Table 1.1 Nigeria’s Health and Socio-economic Related Indicators………………. 3 
Table 3.1 Facility Staff and the Responsibility they Carried out during the Data 
collection……………………………………………………………………………. 52 
Table 3.2 Type of Data, Source of Data, Measurement Instrument and Purpose of the 
Data………………………………………………………………………………… ............. 54 
Table 4.1 Socio-demographic Characteristics of Respondents…………………….. ............. 70 
 
 
 
 
xvii | P a g e  
 
Table 4.2 Clinical Characteristics of Respondents……………………………………. ........ 72 
Table 4.3 Behavioral Characteristics of Respondents…………………………………......... 73 
Table 4.4 Self-reported and Prescription Adherence………………………………….. ........ 75 
Table 4.5 Factors Associated with Adherence Over the Previous Three Days……….. ........ 82 
 
LIST OF APPENDICES 
Appendix 1 University of Abuja Teaching Hospital Health Research Ethics Approval…. ..... ii 
Appendix 2 UMB Forgaty Financial Support……………………………………………. ..... iii 
Appendix 3 Institute of Human virology, Nigeria Health Research Ethic Committee 
Approval…………………………………………………………………………………. ...... iv 
Appendix 4 Participant Information Sheet (English)…………………………………….. ...... v 
Appendix 5 Participants Information Sheet (Hausa)……………………………………........ ix 
Appendix 6 Informed Consent Form (English)…………………………………………...... xiii 
Appendix 7 Informed Consent Form (Hausa)…………………………………………… .... xvi 
Appendix 8 Viral Load Order and Result Form………………………………………… .... .xix 
Appendix 9 Standard Operating Procedure for Viral Load Sample Collection, Processing, 
Storage and Shipment……………………………………………………………………..... xxi 
Appendix 10 Standard Operating Procedure for Blood Collection……………………. .... xxiv 
Appendix 11 Standard Operating Procedure for Viral Load Estimation Using Amplicor HIV-
1 Monitor Test, Version 1.5…………………………………………………………… ..... xxvi 
Appendix 12 Exit Interview Questionnaire……………………………………………..... xxxii 
 
 
 
 
 
 
 1 | P a g e  
 
CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Background 
The United Nations Agency for AIDS (UNAIDS) described AIDS as an epidemic ravaging lives 
at unprecedented levels (UNAIDS, 2008). According to UNAIDS, 22 million out of the 33 
million people living with the HIV globally, were from sub-Saharan Africa in 2007. In 2008, 
Nigeria had the third highest population of people living with HIV in the world with 2.95 million 
people being aware that they were infected with the HIV [Federal Ministry of Health (FMOH), 
2009]. In 2010, AIDS killed 280,000 people out of an estimated population of 3.1 million people 
living with the HIV (FMOH, 2009). 
 
In the Federal Capital Territory (FCT) where this study was conducted, 45,000 people out of a 
population of 1.18 million were infected in 2009 (FMOH, 2010). HIV sero-prevalence rate was 
estimated at 9.9%; HIV and AIDS patients occupy 60% of hospital beds in public health 
institutions in the FCT (Federal Capital Territory [FCT], 2006). 
 
1.2 Country profile 
Geography, population and socio-demographic characteristics 
Nigeria has 36 states and the Federal Capital Territory (FCT) spread across a land area of 
approximately 923,768 square kilometres (Fig 1.1).  It is Africa’s 15th largest country in land 
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mass, the 10
th
 most populous country in the world and the most populous country in sub-Saharan 
Africa. The total population had grown to an estimated 170 million people in July 2012 but the 
population growth rate has decreased from 3.2% in 2006 to 2.6% in 2012 (CIA, 2012). Current 
statistics show that approximately 50% of the total population live in urban areas; the rate of 
urbanization has increased from 2.2% in 2006 to 3.5% in 2012 (CIA, 2012). The population age 
structure indicates that Nigeria has a young population. According to the National Bureau of 
Statistics (NBS) (2011), persons aged 0 to14 years constituted 39.6 %, those aged between 15 
and 64 years (the economically active population), constituted 56.3 %, while those aged 65 years 
and above constituted 4.2 % (National Bureau of Statistics [NBS], 2011).  The gross domestic 
product (GDP) report showed that the Nigerian economy grew by 7.40 % in the third-quarter of 
2011 as against 7.86 % in the corresponding quarter of 2010 (NBS, 2011). Nigeria’s 
unemployment rate increased to 23.9 % in 2011 compared with 21.1 % in 2010 and 19.7 % in 
2009 (NBS, 2011). The rate is higher in the rural areas (25.6 %) than in the urban areas (17.1 %) 
according to the NBS (2011). The NBS (2011) report also shows that 70% of the population is 
living below the poverty line (NBS, 2011).  
 
Health care delivery services are poor in Nigeria; this is demonstrated by the health and 
socioeconomic indicators presented in Table 1.1. The situation may worsen with the HIV/AIDS 
epidemic unless current effort at controlling the epidemic leads to a reduction in the public health 
problems (like tuberculosis) that are driven by HIV/AIDS.  
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Table 1.1 Nigeria’s health and socioeconomic indicators, 2010 
Indicators Estimates 
Life Expectancy at birth: total population (in years)-2012 52 
Total fertility rate (children born per woman)-2012 5 
Total infant mortality rate (per 1,000 live births)-2012 74 
Adult Literacy (15 years & above)- 2003 
                                 Total population 
Female (%) 
Male (%) 
 
68% 
          60.6% 
  75.7% 
 
Source:  2012 CIA World Factbook. 
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Legend 
 
Fig. 1.1 Map of Nigeria showing the 36 states and Abuja, FCT  
Source: National Bureau of Statistics, 2011 
 
 
 
Borno Kaduna Taraba Ekiti Delta Ogun
Yobe Kano Adamawa Kwara Edo Benue Abuja FCT Akwa Ibom Lagos Imo
Kebbi Oyo Kogi Gombe Abia Bayelsa
Zamfara Bauchi Rivers Osun Enugu
Sokoto Katsina Plateau Anambra Eboyi
Jigawa Niger Nassarawa Cross River Ondo
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1.3 HIV/AIDS in Nigeria 
The first case of HIV patient was reported in Nigeria in 1986 (FMOH, 2007). The national HIV 
sero-prevalence level which is obtained through sentinel survey of antenatal care attendees, 
increased from an initial 1.8% in 1991 to 5.8% in 2001. A slight drop to 5% was recorded in 
2003; which stabilized in 2005 with a sero-prevalence rate of 4.4%. In 2008, the prevalence rate 
increased to 4.6%, but dropped to 4.1% in 2010 (FMOH, 2010).  
 
 
 The epidemic is unequally distributed across the 36 states; from 1% in Ekiti State to 10.6% in 
Benue State (FMOH, 2009). The 2008 survey showed that 17 states and the FCT recorded sero-
prevalence of 5% or more. In seven states and the FCT, sero-prevalence was 7% or higher. There 
are also HIV “hot spots”, with prevalence rates higher than the national prevalence rate of 4.1% 
(FMOH, 2010). Wannune, for instance, is a hot spot in Benue State; the HIV prevalence was 
estimated at 21.3% in 2010.   
 
Women are most affected by HIV/AIDS:  58.3% of the infected people (which is a total of 1.72 
million people) living with HIV in 2008 were females. The HIV prevalence peaks at age group 
25-29 years with a sero-prevalence level of 5.6% (FMOH, 2009). The result of mode of 
transmission analysis carried out by the National Agency for the Control of AIDS (NACA) in 
2008, showed that about 62% of new infections occur among persons perceived as practicing 
“low risk sex” in the general population including married sexual partners. The rest of the new 
infections (38 %) are attributable to injecting drug users (IDU), female sex workers (FSW), men 
having sex with men (MSM) who constitute about 3.5% of the adult population (FMOH, 2009). 
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The leading route of HIV transmission in Nigeria is hetero-sexual intercourse, which accounts 
for 80% of all infections. Other routes of transmission include mother-to-child-transmission, 
transfusion of infected blood and blood products, accounting for 10% each (FMOH, 2009).  
 
Few studies have been conducted in Nigeria to evaluate the economic impact of AIDS. 
Bollinger, Stover and Nwaorgu (1999) reported a reduction in labor supply and increased in cost 
among families that are affected by AIDS (Bollinger, Stover and Nwaorgu, 1999).  They also 
argued that the epidemic has had large macroeconomic repercussions due to the loss of lives of 
many individuals during their productive years (Bollinger, Stover and Nwaorgu,1999). Another 
study assessed the economic impact of AIDS on Nigerian households and reported that in 
affected households, a direct private healthcare costs and indirect income loss per HIV-positive 
individual were 36,065 Naira, approximately 56% of annual income per capita. Approximately 
40% of these costs were income losses associated with sickness and care-giving. This study also 
reported that 10% of the cost of HIV is accounted for public subsidies for health and the largest 
single cost, representing 54% of the total economic burden of HIV, is for out-of-pocket expenses 
for healthcare (Mahal, Canning, Odumosu and Okonkwo, 2008). According to the United 
Nations Development Program Human Development (UNDP), life expectancy in Nigeria 
increased from 45 years in 1963 to 51 years in 1991 in the absence of HIV/AIDS but dropped to 
48.4 years in 2010 as a result of the HIV/AIDS epidemic (UNDP HDR, 2010). 
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1.4 The national response to the HIV/AIDs epidemic in Nigeria 
Nigeria initiated the antiretroviral treatment (ART) program in January 2002 in 25 health 
facilities across the country (FMOH, 2007). The facilities enrolled 25 patients each between 
February and June 2002, but the National Institute for Medical Research (NIMR) registered 50 
patients. The program was later expanded to accommodate more patients (an additional 100 to 
500) based on the capacity of the individual centers to care for people living with HIV. The 
Federal Government negotiated with Cipla Pharmaceuticals and obtained a flat price of $350.00 
for a standard triple regimen of Stavudine, Lamivudine and Nevirapine. Personnel including 
doctors, pharmacists, nurses and laboratory staff were trained to treat 10,000 adults and 5,000 
children yearly. An ART committee to guide the implementation of the ART program was set up 
in 2004 to provide technical support for the development of ART guidelines at the national level 
(FMOH/WHO, 2003). The committee consisted of clinicians, pharmacists and other health 
workers. 
 
In January 2006, the Federal Government commenced the free ART program. Records indicated 
that 166,374 patients received free antiretroviral drugs and treatment in 2007, and in 2008, the 
number increased to 247,815. A further scale up to 309,800 patients was reported in 2009; which 
was increased to 380,182 patients in 2010 (Supply Chain Management System [SCMS]/FMOH, 
2011). It is estimated that about 1.5 million people still require ART from an estimated 3.1 
million Nigerians living with the HIV in 2010 (FMOH, 2010). 
 
In the FCT, 30,000 AIDS patients out of the 45,000 people living with the HIV in 2009 were on 
ART. According to the FCT HIV/AIDS Control Program, about 60 health facilities are involved 
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in ART but only 19 of them provide comprehensive ART services including treatment and care, 
laboratory services, HIV prevention, prevention of mother- to- child transmission and home-
based care (FCT HIV/AIDS Control Program, 2009). The other facilities provide only the 
treatment and care and laboratory services. Among the HIV/AIDS treatment centers in the FCT, 
the University of Abuja Teaching Hospital is the largest treatment center. It was treating over 
9,000 AIDS patients in April, 2010 followed by the National Hospital, Abuja and the Asokoro 
District Hospital, which were treating 7000 and 5000 AIDS patients respectively. 
 
 
Despite the enormous challenges controlling the epidemic pose, notable achievements have been 
recorded in the fight against HIV/AIDS. International donors and developmental partners such as 
the United States President’s Emergency Plan for AIDS Relief (PEPFAR), World Bank, Clinton 
HIV/AIDS Initiative (CHAI) and Global Fund to Fight AIDS, Tuberculosis and Malaria 
(GFATM) financially supported ART services at over 150 sites across the nation (FMOH, 2007). 
In addition, faith based and private organizations are also providing ART services under the 
public-partnership scheme. The Clinton HIV/AIDS initiative (CHAI) donated free anti-retroviral 
drugs (adult 2
nd
 line and pediatric 1
st
 and 2
nd
 line) and drugs for treating a wide range of 
opportunistic infections. The PEPFAR is the leading funder of ART activities in Nigeria; in the 
first 4 years of the project (2004 to 2008), PEPFAR had planned to treat 350,000 patients, 
prevent 1.7 million new infections and provide care to 1.15 million patients and AIDS orphans 
(FMOH, 2007). As PEPFAR enters into the 2
nd
 phase of collaborating with the government with 
a focus on quality care, the 4.1% reported national prevalence rate might reduce further. Also, 
the Federal Government budgeted 24,307,729.00 US Dollars for the procurement of anti-
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retroviral dugs in 2010 (SCMS/FMOH, 2011), and this may further strengthen the ART program 
in Nigeria and reduce both the morbidity and mortality of the epidemic. 
 
 
1.5 Problem Statement 
As indicated earlier, ART has been available at both private and public health centers in Nigeria 
since 2002. In 2010, the Federal Government expanded ART services to remote areas that were 
otherwise neglected. The  President, Dr. Goodluck Ebele Jonathan directed that: “all relevant 
government ministries, department, and agencies (MDAs) to accelerate the implementation of 
the decentralization of HIV treatment, care and support services to the primary health care levels 
in all parts of the country” (FMOH, 2010: i). But to maximize the benefits of ART at the primary 
health care levels, sufficient information is required on the factors that constrain or motivate 
adherence to ART. However, only a few adherence studies have been conducted in Nigeria and 
the factors that constrain and motivate adherence in this setting has not been systematically 
investigated. Furthermore, previous adherence studies in Nigeria did not measure adherence in a 
comprehensive way; the investigators used the number of pills taken versus the number 
prescribed criterion to evaluate adherence without taking into consideration whether medications 
were taken at the correct times and on schedule. There is need to conduct a quantitative study to 
describe adherence as well as the factors that constrain or motivate it. The current study therefore 
set out to determine the level of adherence to ART in a comprehensive way (considering the pills 
taken and whether drugs were taken at the correct frequencies and on schedule); the factors that 
are associated with adherence to ART were also evaluated.  
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Introduction 
The chapter is structured into themes which include: definition of terms, key concepts in anti-
retroviral therapy, adherence studies in different settings and the conceptual framework of 
factors associated with adherence to ART.  
 
2.2 Definition of Concepts  
Adherence to Antiretroviral Therapy 
Adherence generally refers to the “extent to which a person’s behaviour - taking medication, 
following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations 
from a health provider” (WHO, 2003a: 3). In the context of the ART, it is defined as taking all 
the prescribed doses at the correct time, in the correct doses and in the correct way (Kgatlwane et 
al., 2006; Roux, 2004; Aspeling, 2006). It involves a change in the patient behaviour base on a 
decision-making process between the patient and health care provider (WHO, 2003a; Bader et 
al., 2006). It also involves the following elements: 
♦ that the medication is taken with or without food, according to the instructions. Some 
medicines need to be taken with food to ensure that the body absorbs them properly while others 
need to be taken on an empty stomach, a certain amount of time before or after eating. It can also 
be important that the patient eats the right kind of food; for example, the amount of fat eaten can 
make a difference to how well some drugs are absorbed. 
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♦ that drug interactions with any other medication is checked. This includes medicines that have 
been prescribed for the patient, or bought at a pharmacy, supermarket or health store, including 
complementary or alternative therapies. Some recreational and illegal drugs can have potentially 
dangerous interactions with ARVs. 
 
Highly Active Antiretroviral Therapy  
The clinical management of AIDS depends on the use of Highly Active Anti-retroviral Therapy 
(HAART) which is defined as a treatment regimen with 3 or more combination of anti-retroviral 
drugs (WHO, 2006a).  According to the Nigerian guideline (FMOH, 2009), the basic first line 
HAART regimens include the following options:  
 Stavudine (d4T) + Lamivudine (3TC) + Nevirapine (NVP) or Efavirenz (EFV) 
 Zidovudine (ZDV) + Lamivudine (3TC) + Nevirapine (NVP) or Efavirenz (EFV) 
 Tenofovir (TDF) or Abacavir (ABC) + Emtricitabine (FTC) or Lamivudine (3TC) + 
Nevirapine (NVP) or Efavirenz (EFV) 
 Didanosine (ddI) + Lamivudine (3TC) or Emtricitabine (FTC) + Nevirapine (NVP) or 
Efavirenz (EFV) (FMOH, 2007).  
The World Health Organization (WHO) recommends 4 regimens for starting ART in ART-naïve 
individuals (WHO, 2009). These are:  
 AZT+3TC+EFV;  
 AZT+3TC+NVP;  
 TDF+ FTC+EFV and  
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 TDF+3TC +NVP 
However, when treatment fails, a wide range of regimens could be used with the Protease 
Inhibitors included in the regimen mix (WHO, 2009).  
 
Non-adherence 
Non-adherence refers to situations when patients fail to take medication as prescribed, take 
medication at the wrong time, skips doses, interrupts treatment for a period or abandons 
treatment altogether (WHO, 2003a). It aslo includes: consistent underdosing, chronic 
overdosing, abrupt overdosing, drug holidays and random drug administration. 
 
Poor adherence 
According to the WHO (2001; 2003a), poor adherence refers to situations when patients take 
antiretroviral medications without compliance to time, schedule and dietary recommendations. In 
this study, non-adherence, poor adherence and suboptimal adherence are used interchangeably.  
 
Fixed Dose Combination (FDC) 
A Fixed Dose Combination (FDC) describes the drug formulation. It is combining many drug 
constituents at fixed strengths in one tablet. For example, the medicine call Truvada has two 
drugs – Tenofovir and Emtricitabine combined at the fixed strengths of 300mg and 200mg 
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respectively. With FDCs, many drugs can be taken in one tablet; which reduces both the pill 
burden as well as the dosing frequency. 
 
Side Effects of Antiretroviral Drugs 
A side effect of a drug is defined as “any unintended effect of a pharmaceutical product 
occurring at doses normally used in humans, which is related to the pharmacological properties 
of the drug” (National Agency for Food and Drug Administration Control- National 
Pharmacocovigilance Centre, (NAFDAC-NPC), 2004: 4). In the context of this study, the side 
effects of the medications are the unpleasant effects patients experienced with those medications. 
For example, Zidovudine may cause anaemia while Nevirapine may cause a fatal condition 
known as Stephen Johnson’s syndrome (Flexner, 2006). These side effects may hinder adherence 
to the prescribed regimen leading to suboptimal adherence to the regimen. 
 
Undetectable Viral Load Level (UDVL) 
The Undetectable Viral Load Level is a level the HIV virus cannot be detected in the blood 
through quantitative laboratory test (Bangsberg et al., 2000; Bangsberg et al., 2003; Bangsberg 
et al., 2001; Paterson et al., 2000; Wood et al., 2003a). In the Nigerian treatment guideline, the 
UDVL is 400 copies/ l
3  
(FMOH, 2007). 
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CD4 
CD4 (cell differentiation at level four) is a type of white blood cells which protect the body 
against infection. When a person has been infected with the HIV for a long time, the number of 
CD4 cells they have goes down, resulting in acquired immune deficiency syndrome (AIDS), in 
which the person’s immune system no longer functions effectively. Consequently, the victim is 
exposed to more attacks by other infections, which further weakens the immunity.   
 
2.3 Adherence to combination anti-retroviral therapy  
Antiretroviral therapy has proved effective at minimizing both the morbidity and mortality of 
AIDS (Mannheimer et al., 2005; Altice, Mostashari and Friedland, 2001), but the success of 
ART relies almost entirely on adherence to ART. Studies found that consistently high levels of 
adherence (95% or more) to a combination of highly active anti-retroviral medications is 
necessary for effective viral suppression, prevention of resistance, disease progression and death 
(Paterson et al., 2000; Bangsberg et al., 2000;
  
Bangsberg et al., 2003; Bangsberg et al., 2001; 
Wood et al., 2003b).
 
According to Wei et al. (1995), using only a single anti-retroviral drug 
inevitably provokes the emergence of drug-resistant virus - in some cases within a few weeks. 
Several prospective comparative trials found that two regimens were more effective than single–
drug regimens (Fischl et al., 1995; Hammer et al., 1996; Saag et al., 1998), and three–drug 
regimens were more effective still (Collier et al., 1996; Gulick et al., 1997; Hammer et al., 
1997). Mathematical models of HIV replication suggest that three is the minimum number of 
drugs required to guarantee effective long-term suppression of HIV replication (Collier et al., 
1996; Gulick et al., 1997; Hammer et al., 1997). The current standard of care is to use at least 
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three drugs simultaneously for the entire duration of treatment. Four or more drugs are often used 
simultaneously in pretreated patients harboring drug-resistant virus, but the number of drugs a 
patient can take is limited by toxicity and inconvenience (Piketty et al., 1999).  
Some studies have argued that viral suppression may depend on other factors other than the 
regimented 95% adherence rate. The drug regimen, for instance, has been shown to affect the 
level of adherence (Weiser et al., 2004; Maggiolo et al., 2005; Bangsberg et al., 2007; Wainberg 
et al., 2007; Bangsberg et al., 2003; Harrigan et al., 2005; King et al., 2005). The un-boosted 
Protease Inhibitors-based combination antiretroviral therapy (cART) requires more than 95% 
adherence to be consistently effective (Friedland, 2006), but the non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and boosted protease inhibitor-based cART can achieve 
virologic suppression at a moderate adherence of 70 – 90% ( Nachega et al., 2007; Shutter et al., 
2007; Martin et al., 2008). Nevertheless, optimal outcomes require optimum adherence (95% or 
more) particularly in the first four to six months of treatment (Gardner et al., 2006; Wainberg et 
al., 2007). This means that: 
 If a patient is taking once-daily treatment, optimal adherence requires not missing  more 
than one dose a month 
 If a patient is taking twice a day treatment, optimal adherence requires not missing     
more than three doses a month 
 If a patient is taking three times a day treatment, optimal adherence requires not missing   
more than four doses a month 
In this study, the 95% adherence rate was adopted as the cut-off level for measuring optimal 
adherence to ART, i.e. patients who took at least 95% of their medications in the past 3 days 
were assumed adherent to the ART.  
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2.4 Poor adherence in Sub-Saharan Africa 
 Optimal adherence rates have been reported in some countries in Africa. Orrell and his 
colleaques (2003) reported a 99% rate in South Africa (Orrell et al., 2003); Nachega and his 
team also reportd 95 % in South Africa (Nachega et al., 2009b) and Jean Baptiste reported more 
than 90% rate in Bostwana (Jean, 2010). On the basis of these studies and others, it was argued 
that adherence to ART is not a problem in Africa. The New York Times reported this great 
achievement with the headline “Africans Outdo US Patients in Following AIDS Therapy” 
(McNeil, 2003). However, suboptimal adherence levels have been reported in some countries in 
Africa: In Cameroon and Senegal, 86% and 80% over-all adherence rates were reported 
respectively (Akam, 2004; Laurent et al., 2002); in Botswana, a 54% over-all adherence rate was 
reported (Weiser et al., 2003) and in South Africa, 80% over-all adherence rate was documented 
(Darder et al., 2004). Furthermore, Gills et al. (2005) commented that the high adherence rates 
reported in most studies in Africa were exerggerated (Gill et al., 2005), suggesting that the actual 
adherence rates in most African countries is unknown. Thus, researchers are concerned that 
Africa may be facing suboptimal adherence as the western countries where studies reported that 
between 100% - 28% of HIV/AIDS patients on ART could not achieve the 95% adherence 
threshold required for viral suppression (Haubrich et al., 1999; Paterson et al., 2000; Bangsberg 
et al., 2000; Gordillo et al., 1999; Gifford et al., 2000).  
 
There are four possible explanations of the poor adherence rates in Africa. Firstly, adherence to 
drugs in the management of chronic conditions such as hypertension, diabetes and cancer has 
generally been a great challenge even in rich western nations (DiMatteo, 2004). HIV/AIDS is 
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also a chronic condition and therefore adherence to the combination ART is a great challenge. 
Secondly, the ART regimens are often complicated and can include varying dosing schedules, 
dietary restrictions and adverse effects (Ferguson et al., 2002).
.
Thirdly, adherence barriers (e.g. 
lack of drugs, forgetfulness and side effects of drugs) have also been reported in many African 
countries (Pinheiro et al., 2002; Fong et al., 2003; Orrell et al., 2003; Weiser et al., 2003; Nemes 
et al., 2004; Stout et al., 2004). These barriers decrease adherence to ART according to studies 
(Ammassari et al., 2004b; Cederfjall et al., 2002; da Silveira et al., 2003; Weber et al., 2004; 
Chesney, 2006; Simoni et al., 2006).  Fourthly, studies show that adherence wane over time 
(Byakika-Tusiime et al., 2009; Carrieri et al., 2003). Laurent and his colleagues (2012), for 
instance, found that after 1 month of therapy, 95% of their patients had adherence exceeding 
80% but after 18 months, only 80% of the patients remained adherent above that level (Laurent 
et al., 2002). The implication of this is that assessing adherence among patients who have been 
on therapy for shorter periods may generate exaggerated adherence rates, since patients may not 
have been on therapy long enough for adherence to start waning (Gill et al., 2005). For this 
reason, only patients who have been on therapy for 12 months and above were included for 
adherence evaluation in the current study. 
 
2.5 Poor adherence in Nigeria 
Nigeria is ranked third among the countries that are worst affected by the HIV/AIDS epidemic, 
yet poor adherence has been reported by the few studies that evaluateed the level of adherence to 
anti-retroviral therapy in Nigeria (Idigbe et al., 2005; Adebayo, Modupeola and Timothy, 2005; 
Daniel et al., 2004; (Uzochukwu et al., 2009); Iliyasu et al., 2005; Farley et al., 2007).  The 
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significant studies were conducted in the South-West, North-Central and South-East geopolitical 
regions of Nigeria. In the South-West, Daniel and his team (2004) measured the level of 
adherence through a cross sectional study in two subsets of HIV infected patients in Sagamu: 
those who were on self-purchased drugs and those on free medications. They included only 53 
participants (40 receiving free medications and 13 on self purchased drugs) who had been on 
ART between 1
st
 Septemeber and 30
th
 November, 2003. They found an overall 79.2% adherence 
rate; the adherence rate was higher among those on free medication compared with those on 
purchased medication but the difference was not statistically significant (Daniel et al., 2004). In 
the North-Central, Farley et al. (2007) assessed adherence using pharmacy refill records and 
patient self-report at the University of Abuja Teaching Hospital. They recruited 529 adults’ 
patients newly initiating ART and evaluated their adherence over six months. They found that 
only 305 (58%) had a refill rate of ≥95% (Farley et al., 2007). In the South-East, an adherence 
rate of 27% was reported by Uzochukwu et al. (2009). They had assessed the adherence rate 
among 174 patients for 12 months through a cross sectional descriptive study (Uzochukwu et al., 
2009). 
 
Although the above studies were limited by sample size, they all reported suboptimal adherence 
rates in the three geopolitical regions of Nigeria; suggesting that Nigeria is struggling with 
adherence to ART. Adherence barriers were also reported by these studies and this has 
compounded the problem of adherence to ART in Nigeria. For instances, psychosocial (e.g. 
forgetting to take drugs), structural (e.g. lack of drugs at treatment centres) and socioeconomic 
factors (e.g. poverty) have been found to be the cause of poor adherence to ART in Nigeria 
(Uzochukwu et al., 2009). The structural factors were considered the major cause of poor 
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adherence before the introduction of the free drug scheme by the Federal government but with 
the introduction of the free drug scheme, the psychosocial and the socioeconomic factors are 
now the leading cause of poor adherence to ART (Uzochukwu et al., 2009).  
 
2.6 ART failure 
The Nigerian national treatment guideline defines treatment failure based on three parameters: 
virological, immunological, and clinical (FMOH, 2007).  Virological failure means any of the 
following conditions: when the viral load is not suppressed to undetectable levels after 6 months 
on ART or viral load is not reduced by at least 2 to 2.5 log10 in HIV RNA level after 24 weeks on 
the ART or a persistent increase in viral load following a period of adequate suppression. 
Immunological treatment failure refers to situations when immunogical test shows a return of 
CD4 cell count to pre-therapy baseline level or 50% decline from on-therapy CD4 cell peak level 
or a failure to achieve a CD4 cell count increase of 50 to 100 cells/ l
3 
per year. Treatmnt fails 
clinically when new opportunistic infections occur or malignancy (signifying clinical disease 
progression) is reported or recurrence of WHO Stage 3 defining conditions (e.g. Kaposi’s 
sarcoma) (FMOH, 2007). The virological and immunological parameters provided the theoretical 
basis for the collection of the clinical data (CD4 and Viral load) in the current study. 
 
2.7 Measuring adherence to ART 
 There is no gold standard for the measurement of adherence to ART; thus the use of surrogate 
measures has been adopted for measuring adherence to ART (Chesney, 2006; Fogarty et al., 
2002; Wagner, 2002; da Salviera et al., 2003; Roux, 2004; Levine et al., 2006; Liu et al., 2006; 
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Marias, 2006; Simoni et al., 2006; Dzinza, 2007). The commonly used methods in research and 
clinical settings include pill counts, pharmacy refill records, drug level monitoring, electronic 
drug monitors (EDM) and various self-reporting tools, such as questionnaires and visual 
analogue scales. Chesney (2006) classified these methods into two main groups: observation and 
patient self-report.  
 
Observational methods 
Observational methods include pill counts, pharmacy refill records, medication event monitoring 
systems (MEMS), and biological and therapeutic drug monitoring and directly observed therapy 
(Chesney, 2006).  
 
Pill counts  
The pill count method entails counting the remaining doses of medication that were dispensed to 
the patient in the previous visit. It can be done at the pharmacy when patient come for 
prescription or at home during unannounced visits (Chesney, 2000). According to Chesney 
(2000), a pill count may provide tangible evidence of poor adherence to the ART, because 
returned pills that were left in the container give an indication of the quantities of drugs taken. 
The method is easy, but it has some limitations. Patients could dump pills before visiting the 
clinic and create the false impression that they have been adhering to the prescribed regimen. 
Also, patients tend to forget drug packages or discard them for the fear of stigmatization, it is 
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difficult to accurately determine adherence with this method.  The method also consumes the 
health workers’ time (Liu et al., 2006). 
 
Pharmacy Refill 
This is a dispensing-based method which relies on the use of pharmacy dispensing records 
(Chesney, 2006). The number of days a patient has medication over a period of time is counted 
and divided by the number of days within the review period to get the proportion of days covered 
by drugs. For example, if the patient was dispensed medicine for 145 out of 180 treatment days, 
then the patient’s maximum adherence rate could only be 81%. The greatest advantage of 
pharmacy refill is that the method can be used to measure long-term adherence. However, 
because dispensing data are used, it is impossible to reliably measure if drugs are actually taken 
and because of this, true adherence may be overestimated (Chesney, 2000; International Network 
for the Rational Use of Drugs-Initiative on Adherence for Anti-retrovirals (INRUD-IAA), 2008). 
 
Medication Electronic Monitoring Systems  
This method uses an electronic pill cap that records when it is opened (Roux, 2004). Several 
studies conclude that MEMS is an objective and accurate measure of adherence to ART 
(Chesney, 2000; Liu et al., 2006; WHO, 2006). It allows detailed view of non-adherence which 
correlates with virological outcomes. However, the MEMS are expensive and complex to 
implement (Liu et al., 2006). The method rests on the assumption that opening the bottle equals 
to use. 
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Biological and therapeutic drug monitoring  
CD4+ lymphocyte count and viral load level are regarded as clinical indicators of adherence to 
the ART (Chesney, 2000). A patient adhering to the prescribed regimen is expected to have high 
CD4 count and low viral load level. However, this method is not a reliable indicator for 
measuring adherence to the ART because CD4 count is affected by other factors other than 
adherence to the ART. Similarly, viral load may not accurately measure adherence to ART 
particularly if resistance to the prescribed regimen has developed. 
 
Patient self-reporting methods 
The self-reported methods involve the use of questionnaires which are either administered by the 
participants or administered by an interviewer. Patients may be asked to recall the number of 
times they correctly took their medications over the previous 3 days, 4 days, one week or one 
month. For shorter recall periods (3 or 4 days), patients are asked to recall the doses they took or 
did not take each day in the previous 3 or 4 days. There has not been any evidence to suggest a 
difference between the validity of using a 3 or 4-day recall, which suggests that a 3-day recall 
may be used (Simoni et al., 2006).   
 
As stated earlier, there is no gold standard to measure ART adherence; each measure has its 
advantages and disadvantages. The choice of a measure is often determined by several factors 
including cost and availability of resources (Chesney, 2006). It is suggested that more than one 
measure should be selected to accurately measure adherence to ART (Chesney, 2006). By 
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choosing two measures, the errors inherent in one measure are addressed by the other measure 
(triangulation) and a more realistic adherence rate is determined. In the current study, two 
adherence measures were selected: the pharmacy refill for 360 days and self-report based on a 3 
day recall. For the self-report, respondents were asked to recall the number of pills that they took 
in a dose over the previous 3 days. The 3-day recall was selected, because it is easier for patients 
to recall their experiences with drug intake for shorter periods than they would for longer periods 
e.g., the past one month. It is also less costly and not sophisticated like the therapeutic drug 
monitoring. In addition, the self-report measures are highly correlated with clinical measures of 
viral load (Nieukerk and Oort, 2005).   
 
2.8 Factors that affect adherence to combination ART 
A number of factors have been associated with adherence to ART and are commonly divided 
into intersecting categories:  patient level, treatment regimens, disease characteristics, patient 
provider relationship and clinical setting (Reiter et al., 2003). 
 
2.8.1 Patient level factors 
The patient level factors are divided into socio-demographic and psychosocial factors. The 
socio-demographic factors include age, gender, race, socio-economic (financial income and 
poverty), education and HIV risk factors; while the psychosocial factors include mental 
health, substance abuse, socio-cultural issues and support, knowledge and attitude about 
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HIV and its treatment (Carrieri et al., 2001; Nemes et al., 2004; Murphy et al., 2004; 
Machtinger and Bangsberg, 2005; Mills et al., 2006a; Mills et al., 2006b). 
 
Socio-demographic factors 
Age 
Age may influence adherence to ART. A study conducted in Los Angeles among 148 HIV-
infected adults between the ages 25 and 69 years to examine the effects of older age, cognitive 
impairment, and substance abuse found a higher mean adherence with the older subjects 
compared with the younger subjects (87.5% vs 78.3%; p=0.01). The older subjects were also 
found to be three times more likely to be good adherers than the younger subjects (OR = 3.1, 
95% confidence interval: 1.40-6.76) (Hinkin et al., 2004).  In southern Africa, a cohort study 
revealed that adolescents and young adults who were on the ART had both poorer adherence and 
poorer virologic outcomes than do adults (Nachega et al., 2009b).  The reason that was given for 
this is that younger individuals who depend on care givers for the administration of drugs may 
struggle with adherence when the care givers are not committed to administering the drugs 
(Mehta, Moore and Graham, 1997; Gordillo, del Amo, Soriano and González-Lahoz, 1999; 
Chesney, 2000). Also, younger individuals may be forced by adults to keep their treatment secret 
because of the fear of stigmatization and this affects adherence to the ART among younger 
individuals (Naar-king et al., 2006; Hammami, Nostlinger, Hoerée, Lefèvre, Jonckheer and 
Kolsteren, 2004).   
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Some studies, however did not find positive association between age and adherence. In Brazil, a 
cross-sectional quantitative study evaluated adherence among 195 patients aged 13 years and 
above and found that adherence to ART was not significantly associated with age (Pinheiro, de 
Carvallo-Leite, Drachler and Silveira, 2002). Also, Eldred and his team did not find association 
between adherence and age (Eldred et al., 1998). Some researchers argue that clinician bias 
rather than patients’ actual behavior is responsible for the association between age and 
adherence. Adherence, according to these researchers, is a behavioral issue and cannot be linked 
to age but clinicians often correlate patients’ level of education, living standards and lifestyles, 
and sometimes also age and sex, with their adherence potential (Eldred et al., 1998). In general 
however, older age has been associated with better adherence to HAART (Hinkin et al., 2002; 
Becker et al., 2002; Wutoh et al., 2001) because cognitive status is generally associated with 
successful adherence (Hinkin et al., 2004; Ammasari et al., 2004a). 
 
Gender 
The role that gender plays as the predictor of adherence has been the subject of several studies. A 
prospective cohort study by Berg and his team examined the role of gender difference in 
adherence to ART among 113 AIDS patients that were current or former opiod users at the 
Montefiore Medical Centre’s Substance Abuse Treatment Program in the Bronx, New York, 
USA. The authors found that women were less adherent to HAART than men, with a median 
adherence rate of 46% (IQR 18%- 77%) compared to 73% (IQR: 30% - 93%) (Berg et al., 2006). 
Other studies also showed that women are less adherent to ART than men (Arnsten et al., 2002; 
Turner et al., 2003; Altice et al., 2001; Delgado et al., 2003; Wenger et al., 1999; Montessori et 
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al., 2000; Abriola et al., 2000; Arabe et al., 1998; Montaner et al., 2000). However, a large body 
of researchers have failed to show a significant association between gender and adherence to 
ART (Eldred et al., 1998; Moatti et al., 2000; Wagner et al., 2002; Carrieri et al., 2003; 
Holzemer et al., 1999; Bouhnik et al., 2002; Golin et al., 2002; Gordilo et al., 1999; Chesney et 
al., 2000; Paterson et al., 2000). 
 
The reasons that have been advanced for the contradictory finding on the association between 
gender and adherence to ART included the following: 
 The use of small number of women in studies 
Most studies that found no association between gender and adherence to ART were limited by 
small numbers of women in the studies (Berg et al., 2004). 
 Clinician biases 
As stated above, clinician bias rather than patients’ actual behavior is responsible for the 
inconsistency in the association between gender and adherence; clinicians often correlate 
patients’ level of education, living standards and lifestyles, and sometimes also age and sex, with 
their adherence potential (Eldred et al., 1998). 
 
 Failure to address confounders 
Another possible explanation for the inconsistency in the relationship between gender and 
adherence is the role of confounders. Most studies do not examine social or behavioral factors 
which confound the relationship between gender and adherence to ART. 
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Socio-economic factors 
Socioeconomic factors include financial constrains (e.g. not being able to travel to study centre 
for treatment due to lack of money), lack of financial support and poverty. The World Health 
Organisation (2006) has cited economic support as directly related to the level of adherence to 
the ART. For example, in a cross-sectional study of 195 patients in Brazil, it was observed that 
there was better adherence to the ART among patients who had sustainable occupations and 
could support themselves economically (Gordillo et al., 1999). In many studies financial 
constraints have frequently been cited as a barrier to adherence to ART (Kleeberger, Phair, 
Strathdee, Detels, Kingsley and Jacobson, 2001; da Salviera et al., 2003; WHO, 2006a; Falagas 
et al., 2008).  
 
 Poverty may prevent individuals from following treatment-related dietary advice and traveling 
to treatment centres to receive medications (INRUD-IAA et al., 2008). Poverty has been cited as 
a predictor of poor adherence to ART in sub-Saharan Africa.  In a multi-country adherence study 
in Uganda, Botswana and Tanzania, 20, 163 and 70 participants were interviewed respectively. 
The authors found that lack of food and transport cost (due to poverty) in Botswana respectively 
accounted for 2.1% and 13% of the reasons for missing medications (WHO, 2006b). However, 
in Uganda and Tanzania, poverty did not affect adherence to ART. Medication may induce 
appetite and if patients are poor and lack the food to eat, they may discontinue the medication 
(da Salviera et al., 2003; Kalichman, Simbayi, Kagee, Toefy and Jooste, 2006; Marais, 2006; 
WHO, 2006b; Moratioa, 2007; Spies, 2007; Thobias, 2008). Also, four studies evaluated the 
relationship between poverty and adherence among poor communities in United States; they 
found that individuals
 
living in poverty had suboptimal adherence
 
in the range of 56% to 67% 
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(Bangsberg, Ware and Simoni, 2006).  However, the role of poverty as non-adherence indicator 
has been contentious. Mills and colleques argued that the barriers to adherence among the 
impoverished
 
individuals in the North America studies appeared to be due to poor
 
patient-
clinician relationships, untreated depression, substance
 
abuse, and other factors that are common 
among poor individuals
 
in North American settings rather than poverty itself (Mills et al., 
2006b). It is likely, therefore, that poverty may not be a predictor of poor adherence to ART 
under every circumstance. In the Brazilian study in Pelotas (Southern Brazil), no significant 
association was found between poverty and adherence to ART which further strengthen the 
argument that poverty may not be a predictor of poor adherence to ART under every 
circumstance (Pinheiro, de Carvallo-Leite, Drachler and Silveira, 2002).  
 
Educational level  
Some studies have found positive association between education and adherence to ART. In 
France, a prospective, multicentre, randomized clinical trial at three university-based hospitals, 
examined the impact of an educational intervention on adherence to ART, knowledge, quality of 
life and therapeutic response in a large cohort of chronic HIV infected patients. The study found 
that educational intervention increased adherence in the experimental subjects at 12 month and 
was maintained at 18 month. The health status improved in the 56% of the experimental subjects 
and 50% of the control subjects. The authors concluded that educational intervention improves 
adherence to ART and health status (Goujard et al., 2003). In Pelotas, Brazil, Pinheiro and his 
team found that schooling was positively associated with better adherence; with an increasing 
schooling level, there was an increase in rates of adherence (p=0.02) (Pinheiro, de Carvallo-
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Leite, Drachler and Silveira, 2002). Van Servellen and his colleagues (2002) also found that 
functional health literacy was significantly associated with medication adherence. These authors 
argue that individuals with low level of education may have difficulties recognizing their correct 
current medications whereas, increased level of education provides patients with vital skills 
(planning, organizing and integration), which promote adherence to ART (Pinheiro, de Carvallo-
Leite, Drachler and Silveira, 2002). However, Uzochuwu and team, found formal education to be 
negatively and statistically significantly associated with adherence to ART (Uzochukwu et al., 
2008). Eldred and his team did not find higher education as predictor of optimum adherence 
(Eldred et al., 1998).  
 
The psychosocial factors 
Patient knowledge of treatment and medicines 
Knowledge of the importance of ART adherence and ability to take antiretroviral medications as 
directed (adherence self-efficacy) have a positive effect on adherence. A multi-center study 
among 980 treatment naïve patients found that less-positive beliefs about ART adherence were 
associated with greater stress, depression, and symptom distress but more-positive beliefs about 
ART adherence were associated with better scores on health perception and functional health 
(Reynolds et al., 2004). Lack of knowledge of drugs (correct doses, frequency of administration 
and schedule) are barriers to adherence to ART (Mehta, Moore and Graham, 1997). The ART 
regimens are very complex and may be confusing; as a result, when patients have not been 
sufficiently counselled to know how to use the drugs, adherence becomes a challenge. 
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Social support  
In Rwanda, a multi-site adherence study involving 653 patients on ART found that significantly 
greater proportion of patients who took at least 95% of prescribed antiretroviral drugs had good 
social support compared to those who did not (64% vs 48%, p= 0.03) (Jean-Baptiste, 2008). 
HIV/AIDS is a chronic condition requiring chronic care as such, consistent support from the 
family facilitates adherence to the ART (Chesney et al., 2000; Bearman and La Greca, 2002; 
Simoni, Frick, Lochkart and Liebovitz, 2002; Attawell and Mundy, 2003; Hofer, Schechter and 
Harrison, 2004; Skhosana, 2006; Kagee, Le Roux and Dick, 2007). According to Attawell and 
Mundy (2003), support from a spouse and support groups play a crucial role in HIV medication 
adherence, but social support could be negatively applied when family members choose to 
stigmatize and discriminate against the sufferers. As stigmatization itself has been shown to be a 
barrier to adherence to the ART (Nachega et al., 2004; 2006a), it is argued that social support 
could be used negatively or positively (Van Dyk, 2001; Timmons and Lynch, 2004).  
 
Disclosure of HIV status 
Disclosure of HIV status could either facilitate or compromise adherence to the ART. When 
patients are stigmatized after disclosing their status, they may suffer psychological depression 
and be discouraged from taking drugs. Under this condition, disclosure of HIV status becomes a 
barrier to the ART (Ormazu, 2000; Klitzman et al., 2004; Zea et al., 2005). In the Botswana 
adherence study, 15% of patients claimed stigma (arising from disclosure of HIV status) 
interfered with their ability to take treatment (Weiser et al., 2003). Some studies claimed that 
disclosure of HIV status promoted adherence to the ART and this was when disclosure attracted 
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family support or assistance from the community or other well-wishers (Nachega et al., 2004; 
2006b).  
 
Attitudes and beliefs 
According to the World Health Organisation (2001) and Mills et al. (2006a), patients’ beliefs 
about their illness and effectiveness of medication are predictive of adherence. For instance, the 
beliefs that anti-retroviral therapy is effective and prolongs life and that poor adherence may 
result in viral resistance and treatment failure can impact positively upon a patient’s ability to 
adhere to the ART (Montgomery et al., 1989; Mehta, Moore and Graham, 1997; WHO, 2001; 
2006b). It is also argued that beliefs in personal abilities to adhere to medication affect adherence 
to anti-retroviral therapy according to Becker (1974) and Pinheiro et al. (2002).  
 
Patient forgetfulness 
In Hong Kong, a retrospective survey of 161 Chinese patients on ART for 1 year found 
forgetfulness to be negatively associated with optimum adherence (Fong et al., 2003). 
Forgetfulness was also shown to be a barrier to ART adherence in many studies (Roberts, 2000; 
Reynolds et al., 2004; Marais, 2006; Mills et al., 2006a; WHO, 2006b; Dieckhaus and Odesina, 
2007; Wang and Wu, 2007; Amberir et al., 2008; Thobias, 2008; Malangu, 2008).  Forgetfulness 
could be due to patients’ being over busy, not using adherence reminders or being away or 
attending important social events such as night vigil, funerals, weddings and parties. Whatever is 
the cause of forgetfulness, adherence to the ART suffers if patients forget to take their drugs 
(Stout et al., 2004). 
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Alcohol and drug abuse 
Studies conducted in Brazil by Chesney et al. (2000) and Palmira et al. (2005) found a positive 
association between alcohol abuse and poor adherence. Another study conducted in Botswana 
also showed that alcohol abuse was one of the reasons patients on the ART was missing doses of 
their medication (WHO, 2006b). Alcohol is thought to induce forgetfulness, which might cause 
patients not to take their medication or take them incorrectly.  
 
Substance (drug) abuse is also associated with poor adherence. The study by Hinkin and team 
which was discussed above also examined the impact of substance abuse on adherence to ART. 
They authors found that drug abuse was positively associated with poor adherence to ART; 13 of 
the 14 HIV-positive participants who met the diagnostic criteria for drug abuse or dependence 
were classified as poor adherers.  
 
The mechanism through which active drug abuse causes poor adherence is unclear. One 
possibility is that drug abuse potentiates HIV-associated neuropsychological compromise, which 
then results in difficulties with adherence (Hinkin et al., 2004). Another explanation would argue 
that the often chaotic lifestyle associated with illicit drug abuse cannot accommodate the 
structure necessary to adhere to a complex medication regimen (Hinkin et al., 2004). But Golin 
et al. (2002) argued that the relationship between substance abuse and adherence is very 
complex. A study by Fogarty et al. (2002) actually found that patients on the ART with a history 
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of substance abuse had better adherence. The reason given for this is that, the discipline drug 
abusers gained from the methadone control programs invariably help them to adhere to the ART 
regimen. 
 
Traveling/busy with work 
Poor adherence has been associated with traveling or being busy (Stout et al., 2004). Over busy 
patients are likely to forget their medication or they may carry them along but forget to take 
them. In the Hong Kong study quoted above, being busy with work was found to be significantly 
associated with poor adherence (Fong et al., 2003). 
 
2.8.2 Treatment regimen factors 
The number of pills prescribed, formulation, complexity of the regimen (dosing frequency 
and food restriction) and the specific type of the ART and medication side effects are 
factors related to the treatment regimens.  
 
Number of pills (Pill burden)       
Taking a greater number of anti-retroviral medications and frequent dosing were found to be 
positively associated with non-adherence (Kleeberger, Phair, Strathdee, Detels, Kingsley and 
Jacobson, 2001; Eldred, Wu, Chaisson and Moore, 1998). Patients with prescriptions of three to 
four daily doses were 53% less likely to comply with treatment than patients who had been 
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prescribed a two-dose regimen (da Salviera et al., 2003). This is because with complex regimen, 
patients commonly misunderstand their health care provider’s instruction on how to take 
medication. In South Africa, a study found that 13% of patients prescribed ARVs were not 
taking their medication correctly, despite believing that they were (Bangsberg, 2000).  However, 
in the Hong Kong study, pill burden, dosing frequency and the need for dietary restriction did 
not predict a poorer drug adherence among Chinese patients who took more than 10 pills per day 
and thrice-a-day (Fong et al., 2003). The authors argued that the counselling program deployed 
to prepare patients for the HAART initiation and the willingness of Chinese patients to follow 
treatment prescribed by the doctors were responsible for the high adherence despite the 
complexity of regimen and high pill burden (Fong et al., 2003). 
 
Formulation of ARV drugs 
The formulation of a drug regimen (i.e. whether it is a fixed dose combination (FDC) or multiple 
single drugs) may also affect adherence. In the Rwanda study discussed above, Jean-Baptiste 
reported a higher rate of adherence among patients taking fixed dose combinations (FDC) than 
patients on multiple drug regimens (Jean-Baptiste, 2008). The fixed dose regimens usually 
require lesser frequent dosing and pill burden than the multiple drug regimens, which explain the 
reason for good adherence with the FDCs. 
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Side effects 
The Hong Kong, Botswana and Rwanda adherence studies found the side effects of medication 
as predictors of non-adherence (Fong et al., 2003; Weiser et al., 2003; Jean-Baptiste, 2008).  
Other studies also cited the side effects of medication as predictors of non-adherence 
(Ammassari et al., 2001; Weiser et al., 2003; Machtinger and Bangsberg, 2005; Weiser et al., 
2003; Roberts, 2000; Pinheiro, de Carvallo-Leite, Drachler and Silveira, 2002; Popa-Lissenanu 
et al., 2005; Mills et al., 2006a; Uzochukwu et al, 2008). However, the experience of symptoms 
and patients’ view about medication side effect may be complex and may vary according to the 
type of regimen (Chesney, 2000; Carr and Cooper, 2000; Ammassari et al., 2001; Carr, 2002; 
Murphy et al., 2004). For instance, symptoms could stimulate the use of medication by acting as 
reminders or reinforcing beliefs about the necessity for treatment but the perception of side 
effects as harmful may constrain the use of medication (Ammassari et al., 2001). It is generally 
believed that treatment burden of long duration, with serious side effects, and potential drug 
interactions, such as the one found with the HAART, manifests significant adherence problems 
(Van Servellen et al., 2002). Horne and his colleagues had argued that missed doses of 
medication may be a logical attempt by the patient to moderate the risk of side effects by taking 
few medications (Horne, 2001).   
 
2.8.3 Patient-provider relationship  
Patient-provider relationship includes the patient’s overall dissatisfaction and distrust in the 
provider and clinic staff, the patients’ negative opinion of the provider’s competency, the 
provider’s unwillingness to include the patient in the decision-making process and the lack of 
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friendliness (e.g. warmth, openness and cooperation) (Chesney, 2000; WHO, 2006 and Marais, 
2006). 
 
A cross-sectional survey of 205 HIV-infected prisoners (most of whom were injection drug 
users) in four prison HIV clinics in Connecticut, USA found  that, trust in physician and in HIV 
medications motivated the rate of adherence to the ART (Altice, Montashari and Friedland, 
2001). In another study, Johnston (2004) examined physician-patient relationships, patient 
satisfaction and antiretroviral adherence among 28 HIV-infected adults in a qualitative study. 
The study found that good quality physician–patient relationships tended to promote adherence 
while lesser quality relationships impeded it. However, in the Rwandan study, patients who were 
non-adherent reported slightly greater satisfaction with their provider than those who were 
adherent (Jean-Baptiste, 2008). 
 
Involvement of patients in decision-making makes the patient to have trust in the health provider 
and clinic staff and increases patient-satisfaction (Barker et al., 2004). Studies have shown 
increase in adherence when patients are involved as active members in the decision-making 
process (Cassidy 1999; Bader et al., 2006). The incompatibility of race/ethnicity between patient 
and provider and the inadequacy of referral have also been cited as determinants of non-
adherence.  
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2.8.4 Clinic setting/health facility factors 
Health facility factors that affect adherence to antiretroviral therapy include quality care, lengthy 
waiting times and distances to health facilities, availability of drugs and follow-up schedules 
(WHO, 2006a).  
 
Availability of drugs and structural barriers 
It is argued that in resource-limited settings, structural barriers are emerging as perhaps the most 
important barriers to the cART (Nachega et al., 2010). A study that surveyed adherence among 
174 patients on ART in South-East Nigeria found that non-availability of drugs in a University 
Teaching Hospital accounted for 65.6% of the reasons patients’ were not adhering to their 
medications. The authors argued that the sustainability of the Nigerian ART program was in 
grave danger unless the government instituted an effective mechanism that would ensure 
consistent supply of medicines (Uzochukwu et al., 2008). In Uganda, a cohort analysis found 
that initially excellent adherence declined over 1 year as patients experienced pharmacy stock-
outs and excess/transportation difficulties (Oyugi et al., 2007). A systematic review of African 
studies also indicated that the most important and frequent factors reported to negatively impact 
adherence in developing countries are cost of drugs and structural barriers such as lack of 
transportation and pharmacy stock-outs (Mills et al., 2006b).  The Botswana study by Weiser 
and team reported that 17% of the patients missed their medications due to running out of 
medication (Weiser et al, 2003).  Patients in rural areas have great difficulties accessing health 
facilities located in townships because of bad roads, long distances and the cost of the transport 
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(Jaffar et al., 2005; Popa-Lissenanu et al., 2005). In the Botswana study, the patients lived 800 to 
1000km away from the clinic and had to travel that distance on monthly basis to access treatment 
(Weiser et al., 2003). Perceived lack of confidentiality and dissatisfaction with past experiences 
with the health care system are also barriers that are related to the clinic. Chesney (2003) found 
that dissatisfaction with the health services is a predictor of non-adherence.  
 
Quality of care 
Patients’ perception of the quality of care they receive affects their behaviour and ultimately 
affect adherence to the ART. Shortage of staff is one major area where quality of care is easily 
affected. It results in overworking of the available staff and overworked staff may be unwilling 
to engage the patients in the planning and management of care, which negatively affect 
adherence to the ART (WHO, 2006b; Attawel and Mundy, 2003). According to Aspeling (2006), 
patients may stop consulting with the clinics temporarily and interrupt treatment when treated 
disrespectfully by health care providers.  
 
Waiting times in health facilities 
In Botswana, Tanzania and Uganda, long waiting time was identified as a major challenge to 
adherence among patients who were on the ART (WHO, 2006b). Dehab et al. (2008) also found 
that prolonged waiting times have negative effects on complying with follow-up appointments 
and medication adherence. The World Health Organization recommended that health facilities 
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should avoid keeping patients waiting for longer periods when they come for consultation and 
medication to maintain high adherence levels over a long period.   
2.8.5 Diseases characteristics  
The stage and duration of HIV infection, associated opportunistic infections, and HIV-
related symptoms are barriers in this category. The severity of the illness could impact 
negatively on adherence particularly, when severely ill patients do not have treatment 
supporters to assist them with drug medication (WHO, 2003a).   
 
Illness-related factors that influence adherence to anti-retroviral therapy such as depression, 
stress and anxiety were reported to be associated with poor adherence in several studies 
(Mehta, Moore and Graham, 1997; Thobias, 2008). Research shows that there is a strong 
relationship between adherence and depression (Ciechanowski, Katon and Russo, 2000; 
Mills et al., 2006a). In an Italian adherence study involving 135 patients on ART, non-
adherence to ART was independently associated with worse depressive symptoms 
(Ammasari et al., 2004a).  Studies had also shown that depressive syndromes are the most 
prevalent mental disorders related to HIV infection (Pinheiro, de Carvallo-Leite, Drachler 
and Silveira, 2002; Starace et al., 2002); also, it has been cited to be having negative effect 
on the quality of life of people living with HIV/AIDS and is associated with poor 
adherence to HIV treatment (Reynolds et al., 2004; WHO, 2006b).   
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2.9 Study designs and methodologies in previous adherence studies 
The review of studies on adherence to anti-retroviral therapy in sub-Saharan Africa revealed that 
most studies used the cross-sectional or longitudinal design over other designs (Gill et al., 2005). 
In Nigeria, all the adherence studies conducted in the past 5 to 10 years used the cross-sectional 
design (Mills et al., 2006b) to describe the scope of adherence to the ART. The cross-sectional 
design is the best design for describing the scope of problems according to Grimes and Schuz 
(2002). 
 
The patient self-reporting measure has frequently been employed in anti-retroviral research 
(Gifford, Bormann, Shively, Wright, Richman and Bozzette, 2000; Eldred, Chaisson and Moore, 
1998; Haubrich et al., 1999; Chesney et al., 2000; Gordillo, DelAmo, Soriano and Gonzalez-
Lahoz, 1999). A meta-analysis of adherence studies conducted in sub-Saharan Africa and North 
America by Mills et al. (2006b) indicated that 71% of the North American studies used patient 
self-report to assess adherence and 66% of the African assessments used the same method. 
According to Pinheiro, de-Carvalho-Leitre, Drachler and Silveira (2002), researchers prefer the 
patient self-reporting measure, because of its practicality, low cost and the fact that adherence 
detected by it has proved to be related to viremia below detection limits (Bangsberg et al., 2000; 
Gifford, Bormann, Shively, Wright, Richman and Bozzette, 2000; Haubrich et al., 1999; 
Chesney et al., 2000) and to serum levels of protease inhibitors. However, studies conducted in 
developed countries to measure the comparative accuracy of the measures of adherence have 
shown a poor association between self-report or pill counts and undetectable viral load (UDVL) 
compared with the association between electronic drug monitoring (EDM) and UDVL. For 
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instance, Arnsten et al. (2001) found that mean HAART adherence rates was 79% by self-
reporting but only 53% by EDM. Moreover, patients whose EDM data indicated high adherence 
(above 90%) was far more likely to achieve UDVL than patients with the same level of 
adherence by self-report. In another study, Liu et al. (2006) concurrently compared several 
measures against patient UDVL rates. He found mean adherence using EDM to be 63% while 
pill count was 83% and self-report to be 93%.  Among patients who failed to achieve UDVL at 8 
weeks, the mean adherence was 87% for self-report, 74% for pill count, but only 59% for EDM – 
indicating that pill counts and self-reporting greatly overestimate adherence. Therefore, 
researchers suggest that more than one adherence measure should be used in assessing adherence 
to the ART (Chesney, 2006). By choosing two measures, it is argued that the errors inherent in 
one measure are addressed by the other measure (triangulation) and a more realistic adherence 
rate is determined.  
 
2.10 Adherence in different settings 
Gill and his colleagues enumerated some of the gaps in previous adherence studies 
conducted in sub-Saharan Africa (Gill et al., 2005). According to these authors, some of the 
studies were part of clinical trials or other highly controlled patient environments such as 
the Khayelitsha study in South Africa (WHO, 2003b). They argued that the studied patients 
may have benefitted from the structural supports provided by the trial and as such, 
adherence rates cannot be generalized to normal settings (Gill et al., 2005). Furthermore, 
longitudinal studies that used self-report measure, according to the authors, took smaller 
sample sizes of patients who have been on the HAART for short periods. The median 
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sample size in a meta-analysis of African studies was barely 100 (Gill et al., 2005). Also, 
most of the studies (66%) used the recall measure to assess adherence, but could not 
validate adherence, because viral load tests were either not available and where available 
were too expensive to be incorporated into routine clinical care. The authors concluded 
these short comings had exaggerated adherence levels in Africa and accurate adherence 
rates remain unknown (Berg and Arstein, 2006; Gill et al., 2005). 
 
2.11 Summary  
The factors that influence adherence to anti-retroviral therapy (patient, socio-economic, 
health service, therapy, illness and the community factors) identified in the preceding 
literature review can be summarised by a conceptual framework (Figure 2). These factors 
interact, resulting in poor adherence to anti-retroviral therapy among patients, and form the 
conceptual basis for the current study (WHO, 2004). 
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Figure 2:1. Factors leading to poor adherence to ART 
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CHAPTER THREE 
          METHODOLOGY 
This section describes the aim and objectives of the study, the study design, how the study was 
conducted and the strategies that were adopted to improve validity, reliability and 
generalizability of the study as well as the ethical considerations. 
 
3.1 Aim of the study 
The current study aimed to describe adherence to anti-retroviral therapy among adult 
AIDS patients (aged 18 years and older) who had been on HAART at the University of 
Abuja Teaching Hospital, over the period of 2005 - 2010, and analyze the factors that 
constrain (barriers) and motivate (facilitators) adherence to ART.  
 
3.2 Objectives 
The specific objectives of the study were: 
 to measure the level of adherence to ART in the FCT 
 to describe socio-demographic characteristics of adult ART patients on the HAART  
 to describe clinical characteristics of adult ART patients  
 to analyze the determinants of adherence to antiretroviral therapy.  
 
3.3 Study setting 
The current study was conducted at the ART clinic of the University of Abuja Teaching 
Hospital, Gwagwalada - otherwise called the Special Treatment Clinic (STC), in order to mask 
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its identity and minimize stigmatization of the patients (Figure 3.1). The STC was created in 
2005 through the PEPFAR collaboration with the Federal Government of Nigeria (FGN). It is 
managed by the AIDS Care and Treatment in Nigeria project (ACTION) – a joint initiative 
between the Institute of Human Virology of the University of Maryland School of Medicine 
(USA), Institute of Human Virology Nigeria, Federal Ministry of Health and the University of 
Abuja Teaching Hospital. The clinic has fully established counseling, pharmacy, laboratory and 
treatment units.   
 
In May 2010, over 9,000 AIDS patients were registered for ART at STC. The records of clinic 
attendees as at 2010 show that 38% of patients were from  the FCT region, 8% from 
Gwagwalada town, 34% from states that are at least five hours drive from the FCT region, and 
18% from the neighboring states that are one to two hours from the FCT.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: A cross section of the University of Abuja Teaching Hospital, Gwagwalada, FCT, 
Nigeria 
Source: The Department of Administration, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria. 
 
A Cross Section of the University of Abuja Teaching Hospital, 
Gwagwalada, FCT, Nigeria 
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The clinic provides services daily excluding weekends; to an average of 100 patients. There are 
between 5 and 8 doctors, 4 pharmacists, 3 adherence counselors and 10 nurses in the clinic. At 
ART enrollment, patient’s history is taken by the nurses and physical examination conducted by 
the doctors in order to complete an intake record which included demographic data. Adherence 
counseling is routinely provided to patients and a regimented intensive HIV treatment 
preparation program is offered as part of routine clinical care. The National Guideline for HIV 
and AIDS Treatment and Care in Adolescents and Adult is used and five different anti-retroviral 
treatment regimens were prescribed during the study. Cotrimoxazole and other opportunistic 
infection drugs were also used to manage co-infections. The choice of regimen is at the 
discretion of the physician which is based on the national treatment guide line.  
 
 
Patients are scheduled for a follow-up visit one month after ART was dispensed for the first 
time, and then every two or three months at the discretion of the physician.  A sufficient supply 
of medication is dispensed to last until the next scheduled visit and at each follow-up visit, 
patients are given a health talk, their history taken and physical examination conducted. In 
addition, any side effects reported are recorded by the physician/pharmacist /nurses on a clinical 
encounter form called the Pharmacovigilance form. A pharmacy order form (prescription), which 
includes date the medication was dispensed, formulations dispensed, and quantity of formulation 
dispensed, is completed by the physician or nurse at each visit and presented to the pharmacist 
for dispensing. Clinicians review patients for treatment failure using the treatment failure 
algorithm. Patients who have been on therapy for six months and more, and are showing 
evidence of treatment failure (predicted through the viral load level, CD4 count and opportunistic 
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infections) are sent to the laboratory to have a fresh viral load test conducted. Physicians use the 
viral load order form (Appendix 8) to request for such tests.  
 
 
3.4 Study design 
The study used an observational, descriptive and analytical, cross-sectional survey design. This 
design was selected for four reasons. First, it is the recommended design for studies that describe 
the scope or the extent of research problems (Grimes and Schuz, 2002; Beaglehole, Bonita and 
Kjellstrom, 2006). Since the aim of this study is to describe the scope of adherence and its 
determinants, the cross sectional survey design was adopted. Second, literature review showed 
that similar adherence studies have used this design with outstanding results (Weiser et al., 2003; 
Bangsberg et al., 2000; Pinheiro, de Carvallo-Leite, Drachler and Silveira, 2002). Third, 
generalization of findings to the study population is feasible, because the design allows a cross 
section of the study population to be examined at a given time (Durrheim and Painter, 2006; 
Park, 2007). Fourth, very few ethical difficulties are associated with it. However, the causes of 
problems cannot be identified because causal relationships cannot be established with the cross 
sectional design (Grimes and Schuz, 2002).  
 
 
3.5 Study population and sampling 
The study population comprised of all adults (18 years and older) who have been treated with the 
HAART medications for at least 12 months as at May 2010. The criterion of a minimum 12 
months treatment was chosen for three reasons. Firstly, it may take 6 months or more for some 
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patients to achieve undetectable viral load after treatment initiation or switch (Paterson et al., 
2000; Pradier et al., 2001; Clay, 2005) and the study relied on patients’ viral load to validate self-
reported adherence. Secondly, HAART is a life-long treatment; it is therefore more meaningful 
to evaluate longer term, rather than short-term adherence to the HAART. Thirdly, patients who 
have been on therapy for short term are likely to have very high rates of adherence, because 
adherence falters after patients have been on therapy for longer terms (Akam, 2004; Carrieri et 
al., 2001; Laurent et al., 2002). Patients who were critically ill or hospitalized as well as those 
who were not currently taking ARVs or had defaulted for 4 months within the 360 days were 
excluded from the study.  
 
 
Participants’ preparation for sampling 
The participants were prepared for sampling at the “health talk hour”. As part of routine care, the 
facility conducts a compulsory one-hour health talk (8-9am) for all HIV positive patients visiting 
the ART clinic to refill their medication prescriptions. During the health talk (Figure 3.3), the 
study’s aim, eligibility criteria, viral load test, confidentiality and benefits of the study were 
presented to the patients by the nurses and adherence counselors who were responsible for 
coordinating the health talk. Participants were allowed to ask questions on the study after the 
presentation. 
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Figure 3:2. An interactive session 
 
 
Sampling strategy 
Prior to going to the dispensary to refill prescriptions, nurses arranged patients in rows on the 
basis of “first-come-first-serve” and they waited patiently to be called to refill their prescriptions 
by the pharmacists. It took about 10 minutes for pharmacists to attend to a patient; therefore, 10 
minutes was used as the sampling interval for the selection of the participants.  
 
The first patient that was selected to be included in the study was called to the dispensary after 
she met the criteria and gave consent. After that, every person was selected at every 10
th
 minute 
interval.  Dispensing pharmacists checked the pharmacy records and patients who were 18 years 
and above who had been taking their ARVs for at least 12 months as at May 2010 were further 
informed of the study’s aim, benefits and risks and if they were willing to be interviewed, were 
directed to the interview center, which was opposite the dispensary. If the patient declined, the 
next patient was invited at the 10
th
 minute interval and his consent requested. The same 
A Nurse giving talk in an interactive  session 
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procedure was repeated until the sample size was realized. 
 
A systematic sampling was adopted for the recruitment of respondents, as used by Bangsberg 
(2000). Systematic sampling was convenient both for the patients and the data collectors; it did 
not have the rigor of simple random sampling (Durrheim and Painter, 2006). 
 
Sample size determination 
A non-adherence rate of 42% from a study conducted at the study center by Farley et al. (2007), 
and an error margin of 5% and 95% confidence level were applied as parameters for sample size 
calculation. These figures were built into a statistical formula (Joubert and Katzenellenbogen, 
2007) and a minimum sample size of 374 was derived. However, a larger sample size was 
chosen to increase its power (Durrheim and Painter, 2006; Hedges, 1978). Therefore, the 
minimum sample size derived from the calculation (374) was raised to 502. 
 
3.6 Data collection 
Pretesting of questionnaire and pilot study 
The questionnaires were pre-tested in two phases. During the first phase, its content was 
evaluated for content validity using current literature and one HIV/AIDS clinical expert at the 
study centre. Suggestions were discussed and incorporated where necessary. During the second 
phase, the proposed process for identifying and interviewing patients was evaluated. Two health 
providers identified ten eligible patients who were approached by the data collectors for 
interviews. Three key lessons were learnt during the exercise: the questionnaire was too long to 
be administered in 3 to 5 minutes, some important questions that should have been included in 
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the questionnaire were omitted and some of the participants were upset for the fact that their 
occupations/professions were not specifically listed in the questionnaire. For instance, the pastors 
were not happy to be classified as “civil servants”. Based on the lessons taken from this exercise, 
the questionnaire and the data collection process were modified. The revised questionnaire 
(Appendix 12) and data collection process were used in subsequent data collection efforts as 
described. 
 
Logistics of data collection 
Prior to data collection, several meetings with individuals and groups of health workers at the 
study center were held. The ART Coordinator, ART Facility Manager, Clinical Associate (CA) 
and the heads of Pharmacy, Treatment Support Specialist (TSS), Monitoring and Evaluation, 
Records and Laboratory Services were presented with the research approval letters from the 
University of Abuja Teaching Hospital (Appendix 1) and the Institute of Human Virology, 
Nigeria (Appendix 3). The roles the different health workers performed to ensure smooth data 
collection were fully discussed and agreed upon during the meetings. In Table 3.1, the specific 
responsibilities of the workers are presented. 
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Table 3.1:  Facility staff and the responsibility they carried out during the data collection 
Health Staff Specialty Responsibility 
ART Coordinator Physician Coordinated the data collection  
Clinical Associate Physician Ordered the viral load tests  
Facility Manager Nurse  Coordinated the data collection. 
Phlebotomists Medical Laboratory Collected blood for viral load assay 
Medical Laboratory 
Scientists 
Medical Laboratory 
Science 
Performed the Viral Load Assay 
Pharmacists Pharmacy Screened patients for inclusion  
Nurses Nursing Introduced the study at the health 
interactive session 
Monitoring and 
Evaluation Staff 
Statistician Extracted patients’ prescription 
refill record from CAREWare 
Record Staff Sociologist Extracted patients’ CD4 from 
folders  
Treatment Support 
Specialists  
Community health 
workers  
Motivated respondents to 
participate in the study 
 
 
On the days of data collection, data collectors arrived at the study center one hour (7am) before 
the clinic opens with the health interactive session. The principal investigator went round and 
thanked the health workers for assisting with the data collection and solicited for continued 
support. Emerging problems or challenges reported the previous day by the data collectors were 
raised and resolved with the workers during the thank-you visits. The lady who was contracted to 
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provide snacks was also visited routinely to ensure that the quality of snacks recommended by 
the ART Coordinator was what was presented. Interviews started around 10: 00 am and ended by 
3:00 pm daily except on Mondays when it started late because of the clinical meetings. The types 
of data collected, sources of the data, the measurement instruments and the purpose of the data 
are out-lined in Table 3.2. A description of how the data were collected is presented under the 
ethical consideration section. 
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Table 3.2 Type of data, source of data, measurement instrument and purpose of the data 
Type of data Source of data Measurement 
Instrument 
Purpose of data 
Socio-
demographic and 
Adherence 
(patients’ 
experience with 
use of ARVs) 
Adult patients on 
ART for at least 12 
months 
Exit questionnaire To measure short term 
adherence ; To measure 
adherence barriers and 
socio-demographics of 
patients 
Viral load  Consented 
respondents who 
were interviewed  
Amplicor HIV-1 
Monitor Test, 
Version 1.5 
To validate adherence 
information 
Patients’ 
Prescription 
|Refill 
CAREWare 
(software) 
Retrospective 
pharmacy form 
To measure long term 
adherence  
Patients’ clinical 
characteristics 
(CD4) 
Patients folders Patients clinical 
characteristics form 
To measure clinical 
characteristics and 
validate adherence 
information 
 
 
Procedures/processes for data collection 
The socio-demographic and adherence data using the exit questionnaire 
Data collectors asked questions in English but for patients who could not understand English, 
Hausa was used and for this reason, the consent and participants’ information sheet were 
translated into Hausa by a certified Hausa translator (Appendixes 5 and 7).  Participants were 
permitted to voice any questions and whether or not he/she would consent to participate and 
those who consented were asked to sign or thump print informed consent forms (Appendixes 4 
and  6) before the interview commenced using the exit questionnaire.  Data collectors signed 
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confidentiality forms to maintain confidentiality on patients’ information. Anonymity was 
maintained throughout the study – patients’ names did not appear on interview forms. 
Participation was completely voluntary and those who chose to withdraw at any stage from the 
study were allowed to freely do so.  
 
The questionnaire was a structured interviewer-administered questionnaire; built on work done 
by the INRUD-IAA, and modified to fit the study objectives and local situation in the FCT. 
Items on the questionnaire included: socio-demographics and adherence information. For 
instance, participants were asked how long they waited at the clinic, how long it took to travel to 
the clinic, how many of their prescribed ARVs and other drugs were actually dispensed, whether 
the medicines were correctly labeled, whether they experienced any adverse drug events. The 
questionnaire also evaluated patients’ knowledge of drug regimen, e.g., whether participants 
knew how to take their medicine correctly with respect to dosage, frequency of administration, 
compliance with food restrictions and whether medicines were taken on schedule. Adherence 
determinants classified into five groups: patient variables, treatment regimens, disease 
characteristics, patient provider relationship and clinical setting were examined using the 
questionnaire. These variables were evaluated because studies have shown that they might 
potentially have an impact on adherence to ART in resource limited settings (Pinheiro, de 
Carvallo-Leite, Drachler and Silveira, 2002; Fong et al., 2003; Orrell et al., 2003; Weiser et al., 
2003; Nachega et al., 2004; Nemes et al., 2004; Stout et al., 2004; Byakika-Tusiime et al., 2005; 
Safren et al., 2005). 
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Viral load data using the Amplicor HIV-1 Monitor Test, Version 1.5  
                                                                                                                                                                                                                                          
The Clinical Associate (CA) requested for the viral load test to be conducted by signing the viral 
load order form (Appendix 8). After the participants were interviewed by the data collectors 
(Figure 3.3), they presented the signed form to the facility’s Phlebotomist who took blood 
samples. The Phlebotomists used a standard protocol approved by the ACTION project to collect 
process and transport blood samples for the viral load assay (Appendixes 9 and 10). Processed 
blood samples were shipped to the PEPFAR laboratory for the viral load assay according to the 
standard protocol (Appendix 11).   
 
 
 
 
Figure 3.3 A Phlebotomist taking blood sample from a participant 
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Viral load assay 
The PEPFAR trained medical laboratory scientists used the approved ACTIONs’ viral load assay 
protocol (Appendix 11) for the assay (Figure 3.4). Viral load results were recorded in the viral 
load template and then extracted into the viral load form (Appendix 8) for the data analysis. 
 
 
 
Figure 3.4 A PEPFAR trained medical laboratory scientist performing viral assay 
 
The Amplicor HIV-1 Monitor Test, Version 1.5 was used for the assay. The instrument measures 
the plasma HIV-1 viral load using the Polymerase Chain Reaction (PCR) and could detect up to 
200 copies of viral RNA and is used to monitor the effects of anti-retroviral therapy by 
measuring changes in plasma HIV-1 RNA levels during the course of anti-retroviral treatment. 
However, the base line for viral undetectability according to the Nigerian treatment guideline is 
<400 copies/µl
3
. Participants with viral loads above this level were reviewed by clinicians and 
treatment regimen switched. In the data analysis, <400 copies/µl3 was used as the base line for 
validating adherence information provided by the participants.  
 
Viral Load Assay in progress 
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Patients’ prescription refill data using CAREWare 
Data generated by pharmacists during routine dispensing are entered in real-time into 
CAREWare – computer software for health management information system. The data include 
the identity of the patient (name, hospital number and PEPFAR ID), date ART was initiated, date 
medications were dispensed, the formulations dispensed and the quantity of each formulation 
dispensed.   
 
During the data collection, the facility CAREWare specialist was given a list with hospital 
numbers and PEPFAR IDs of participants who were interviewed. The prescription refill records 
of each participant for 360 days, starting from May 2009 to April 2010 were collected and 
entered into the retrospective pharmacy record form for analysis. To maintain participants’ 
confidentiality, prescription refill data did not reflect their names and the captured data were 
destroyed immediately the relevant ones were extracted into retrospective pharmacy record form.  
 
Patient CD4 data using the patient folders 
As part of routine clinical care, physicians conduct physical examination and order for laboratory 
tests, CD4 counts as well as other tests vital for both managing and reviewing the progress of 
treatment. Data generated from the laboratory tests and physical examinations are entered into 
the patient’s folders and are retained in the record department.  During the data collection, the 
facility record staff in charge of the folders was given a list containing the hospital numbers and 
PEPFAR IDs of the 502 participants who were interviewed. He extracted the participants’ latest 
CD4 and entered them into the patient clinical characteristic form for data analysis. 
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3.7 Data Management 
To ensure data integrity during the data collection phase, efforts were made to streamline the 
process and maintain confidentiality. All forms necessary for a particular interview (i.e., 
participant’s identification, consent form, data collection tools and viral load form) were collated 
and placed in plastic bags so that interviewers could easily pick up full and complete 
interviewing packages. Interviewers asked every question in the questionnaire; before leaving 
each interview, they double-checked the questionnaire for any accidental omissions. Whenever 
possible, an attempt was made to obtain any data omitted during the interview from the relevant 
participants. The principal investigator periodically (every two or three days) reviewed data tools 
from interviews for completion. The data were entered into an ACCESS base template and later 
uploaded into secured SPSS master files. To ensure accuracy, the data were double-entered and 
hand-checked. In addition, the data were closely monitored for missing lines, blanks, outliers, 
inappropriate or impossible values, and illogical values for logical combinations of variables by 
evaluating frequency distributions. Data entry was concurrent with data collection, so that to the 
extent possible and necessary, interviewers could be briefed on any noted patterns of data 
collection errors. 
 
3.8 Data Analysis 
Data were captured on Microsoft Excel 2007 and imported in SPSS Version 16 for Windows. 
Descriptive statistics including sum, frequency, mean, mode, median, proportion, range and 
percentage distribution were applied in the analysis of data variables. Measures of association 
were tested by cross-tabulation of variables of interest using Chi-square. A p-value of less than 
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0.05 was considered statistically significant. All co-variables (e.g. age) with p<0.05 were 
described as having significant effect, difference or influence on the variable of interest (missed 
dose adherence or prescription refill adherence). Both sets of criteria for measuring adherence 
(not missing dose, correct dose, frequency and schedule) were analyzed using descriptive 
statistics. 
 
Analysis of adherence to ART 
 Five criteria, namely not missing a dose, correct dose, correct frequency, correct schedule and 
total adherence, were used to assess adherence by self-report  
 
a) “Not missing a dose” criterion 
To assess adherence by not missing dose criterion, participants were asked, “How many of the 
doses did you miss in the last 3 days?” The responses they gave were cross checked against a set 
of options: 0, 1, 2, 3, 4, 5 and 6; representing the possible doses a participant could missed in 3 
days. For a medication that is taken twelve hourly (most of the ARV drugs are taken twelve 
hourly), a maximum of 6 doses are taken in 3 days (2 x 3).  To achieve ≥95 adherence, a patient 
can only miss 0.3 doses in three days (5.7 x 100/6). A participant was considered adherent under 
this criterion if he/she missed 0.3 doses but since missing 0.3 doses is equivalent to not missing a 
dose, patients that did not miss a dose in the past 3 days were considered adherent. 
 
b)   Correct dose adherence criterion 
To assess adherence by correct dose, participants were asked, “In the last 3 days, how many 
A data collector exhibited maximum  
 
concentration while asking questions 
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tablets of this medicine did you take in one dose?” The responses they gave were compared with 
the officially approved doses to determine whether the correct dose was taken or not. If the 
correct dose was taken, the interviewer ticked the option, “Yes” and “No” if the wrong dose was 
taken. A participant was considered adherent under this criterion if he/she reported taking 95 – 
100% of the correct doses in the past 3 days.  
 
c) Correct frequency adherence criterion 
To measure adherence by this criterion, participants were asked, “In the last 3 days, how many 
times in a day did you take this medicine?” The responses they gave were compared with the 
officially approved frequencies to determine whether the correct frequency was complied with or 
not. If there was compliance with the correct frequency, the interviewer ticked the option, “Yes” 
otherwise, “No” if there was no compliance. A participant was considered adherent under this 
criterion if he/she reported complying with the correct frequencies at a level of 95 – 100% in the 
past 3 days.  
 
d)  Correct schedule adherence criterion 
A schedule refers to the time interval between doses. For instance, a drug regimen that is taken 
two times daily will require a twelve-hour time interval; the first dose taken at 7am and the 
second dose taken at 7pm to maintain the twelve-hourly interval. To measure adherence by this 
criterion, participants were asked: “At what times were you taking this medicine in a day for the 
past 3 days (specify the hours e.g. 8am and 8pm)?” The response they gave was compared with 
the officially approved schedule to determine whether the correct schedule was complied with or 
not. If drugs were taken on schedule, the interviewer ticked, “Yes” otherwise, “No,” if outside 
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schedule. A participant was considered adherent under this criterion if he/she reported complying 
with the correct schedule at a level of 95 – 100% in the past 3 days.  
 
e) Total adherence 
Total adherence was measured on the basis of taking 95–100% of prescribed drugs in correct 
doses, correct frequencies and correct schedule during the previous three days. 
 
Prescription refill adherence 
Adherence by prescription refill is defined as having medication for 95% of the review period – 
the review period was 360 days (May 2009 to April, 2010). A patient who had 95% of review 
period covered by the ART medications is considered adherent by prescription refill.  It is 
calculated using the formula:  
 
Adherence Rate = Number of days covered by drugs x 100 
                                          Review Period (in days). 
 
3.9 Validity 
The validity of the study was enhanced by minimizing selection and information biases (Myer 
and Karim, 2007). 
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a) Selection bias 
Selection bias was minimized by adopting inclusion criteria that ensured the sample has the same 
characteristics with the target population. Furthermore, each respondent had an equal and 
independent chance of being selected by the systematic sampling strategy applied.  
 
b) Information bias 
Validation of self-reported adherence with viral load testing 
Social desirability bias, in which participants respond to particular questions with the answers 
that they consider to be most socially desirable (or least stigmatizing), rather than answering with 
complete honesty, is a significant bias with the self-reported adherence (Chesney, 2006; Myer 
and Karim, 2007). To control for information bias, viral load test was requested from 
respondents who consented to the interview. As optimum adherence correlates with undetectable 
viral load level (UDVL) (Paterson et al., 2000; Arnsten et al., 2001), it is argued that 
respondents who have been taking their medications as prescribed for a long period should have 
undetectable viral load level. So, by measuring both validated viral load adherence and non-viral 
load adherence, social desirability bias was largely accounted for.  
 
 
Exit interviews 
Asking questions in a consistent way minimizes information bias (WHO, 2008). Hence, 
questions were asked in a consistent way using the structured exit questionnaire. For instance, 
“In the last 3 days, how many tablets of this medicine did you take in one dose?” and “How 
many of the doses did you miss in the last 3 days?” were consistently asked to all the 
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participants. Additionally, data collectors were friendly and non-judgmental as they asked 
critical questions on adherence (Fig. 3.5). 
 
 
 
Figure 3.5 A data collector being friendly during an interview with a participant 
. 
 
Training of data collectors 
Four Pharmacy graduates (two males and two females) were recruited for the data collection. 
They were fluent in Hausa and English and could use either of the languages depending on 
which one the respondents could understand. Additionally, they were indigenes of local 
communities who share similar culture and traditions with majority of the respondents so that 
cultural differences did not inhibit data collection.  
 
Training slides on the basic concepts of ART and adherence to ART were developed using the 
Nigerian treatment guideline and the most current literatures on the subject. The International 
Network for the Rational Use of Drugs-Initiative on Adherence for Anti-retrovirals (INRUD-
A data collector 
jovially 
interviewing  
a respondent 
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IAA) was contacted through Professor Richard Laing and John Chalker and additional training 
slides on data collection were provided. These slides were utilized throughout the duration of the 
training which lasted for three days consecutively.  
 
During the training, data collectors were instructed to ask questions in simple English. However, 
for patients who could not understand English, Hausa was to be used. Collectors were further 
instructed to ask questions in a unified way and to be pleasant and polite rather than being 
officious or speak with technical words. They were also to dress casually so as to make the 
participants to feel at home in giving real information. Practical demonstration on how the data 
would be collected was presented using the collectors as the participants. The data collectors 
were allowed to ask questions and made in-puts on the logistics of data collection during the 
training. The cost of transportation and the little financial assistance for the collectors were 
discussed and agreed upon. From the financial support provided by the UMD Fogarty AITRP 
(UMD AITRP 5-D43 TW 01041) (Appendix 2) for the study, each data collector was paid N10, 
000.00 ($67.00) at the end of the data collection period, which lasted for two and a half months. 
Also, data collectors were trained to conduct interview with a deep sense of concern, care and 
friendliness so as to get real information from the participants  
 
Anonymity of data collectors  
The data collectors had no knowledge of the participants and their past experiences with the use 
of the ART medications. Furthermore, they were not health staff of the study center as a result, 
the respondents were free to speak about their experiences with the use of the medications 
because they knew that any information they provided would be kept confidential. Thus, the 
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information they provided was likely to be honest. 
3.10 Reliability 
According to studies, the reliability of a study can be enhanced by addressing two factors: 
random sampling error and random measurement error (Myer and Karim, 2007).  
 
Random sampling error 
To minimize random sampling error, a large sample of 502 respondents was taken. It is argued 
that a large sample is similar to the target population than a smaller sample and similarity of the 
sample to the target population minimizes random sampling error (Myer and Karim, 2007; 
Grimes and Schuz, 2002; Beaglehole, Bonita and Kjellstrom, 2006). 
 
Random measurement error 
The use of standardized, tested and precise measurement instruments has been recommended for 
minimizing random measurement error (Myer and Karim, 2007). As a result, the measurement 
instruments that were used namely, the exit interview questionnaire, Amplicor Monitor Test 
Version 5.1 and CAREWare, were tested before they were deployed for the data collection.  
 
The exit interview questionnaire had been pretested in Uganda, Ethiopia, Rwanda and Kenya by 
the INRUD-IAA. As Nigeria is also a resource limited nation as these nations, the tools were 
adopted and pretested twice. First, on the data collectors outside the study center and second, on 
10 respondents randomly selected at the study center. After the pretesting, the tools were 
modified to match the local standard. Modification of the tools with the data collectors improved 
the reliability of the tools and the confidence of the data collectors to use the tools effectively. 
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The Amplicor Test machine was in a functional state before it was deployed for the viral load 
test. Additionally, its precision was tested against a standard test specified in the approved 
protocol. Tests were repeated if the viral load result varied with the result of the standard test. 
 
3.11 Generalizability 
The result of this study could only apply to this study population. However, a large sample size, 
systematic random sampling and appropriate inclusion criteria were adopted to improve the 
generalization of the findings in adult HIV/AIDS patients in the FCT.  
 
3.12 Ethical considerations 
To meet the legal requirements, the study was approved by the human research ethical 
committees of the University of Western Cape (UWC), Institute of Human Virology, Nigeria and 
University of Abuja Teaching Hospital. Furthermore, blood samples were collected in 
accordance with the ethical standards prescribed by the University of Abuja Teaching Hospital 
committee on human experimentation and with the Helsinki Declaration. Also, socio-
demographic and adherence data, viral load, patient’s prescription refill and patients’ clinical 
characteristics data were collected from participants who consented.  Facility Manager, data 
collectors and participants authorized the taking of photographs by a certified photographer. 
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CHAPTER FOUR 
RESULTS 
 
4.1 Introduction 
A total of 537 patients consented to be interviewed; 6 did not have viral load test data. During the data 
cleaning, it was found that 28 participants had incomplete prescription refill data and one (1) was younger 
than 18 years. Thus, 35 participants were excluded leaving a total of 502 subjects entered into the analysis 
(Figure 4.1).  
 
          
  6 Did not have viral load test 
              28 Had in complete in prescription refill  
 1 did not meet age criterion  
  
 
Figure 4.1 Recruitment of patients to the study 
 
4.2 Socio-demographic characteristics of participants 
Equal proportions of females (n=254; 50.6%) and males (n=248; 49.4%) participated in the 
study. Male participants were on average older (p <0.001) than the females; with the median age 
for males being 42 years (IQR: 38 – 44 years) and the females 36 years (IQR: 30-40 years) 
(Table 4.1). Most men were in monogamous married relationships (68.1% vs. 37.8%). 
        537 Consented to be interviewed 
       531 
       503 
      502 
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Significantly (p <0.001) more female than male participants were single (24.8% vs. 15.3%) or 
widowed (25.6% vs. 7.7 %).  More male participants had higher education (71% and 9% had 
secondary and tertiary education, respectively) compared to female participants (63.4% and 
4.7%) (p =0.017). Also, significantly more females than males in the study (13% vs. 5.2%) had 
none or informal education (Quranic education). More men had formal employment (private 
business which includes, artisans (automobile mechanic, furniture makers), business/traders, 
civil servants and professional executives) compared to females  in the study (84.2% vs. 68.9%); 
female participants, on the other hand, were significantly more in the informal employment 
sector (household/domestic work, housekeeping and farming) (p <0.001) (18.9% vs. 9.7%), or 
unemployed (12.2% vs. 6.0% for men, p <0.001) than the males. Most participants were 
Christians (77%); with some Muslims (23%).  
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Table 4.1 Socio-demographic characteristics of respondents 
Socio-demographic 
characteristics 
TOTAL 
n              % 
               Male 
n                           % 
Female 
      n              % 
p 
 
Age (in Years)                                                                                    < 0.001 
< 21                                                                     2 0.40   1  0.4        1 0.4  
21 – 30 84             16.7  16  6.5      68 26.8  
31 – 40 216           43.1  88 35.5    128 50.4  
41 – 50 148            29.5 104 41.9      44 17.3  
51 – 60 49               9.8  38 15.3      11 4.3  
>60 3                0.60    1   0.4        2 0.4  
Marital status < 0.001 
Single 101          20.1 38 53.3      63 24.8  
Married, monogamous 265          52.8 169 68.1      96 37.8  
Married, polygamous 38             7.6 18 7.3      20  7.9  
Widow   98           19.5  23 9.3      75 29.5  
Education     0.017 
None/Informal      46            9.2 13   5.2      33 13.0  
Primary 84           16.7 36 14.6     48 18.9  
Secondary 337         67.1 176 71.0    161 63.4  
Tertiary 35            6.9 23   9.2      12   4.7  
Occupation  <0.001 
Formal Employment 384           76.5 209 84.2     175 68.9  
Informal Employment  72            14.3 24 9.7      48 18.9  
Unemployed 46             9.2 15 6.0      31 12.2  
Religion            0.597 
Christianity                          
Islam  
Traditional            
388           77.3 
113           22.5 
1             0.0004 
191 
56 
1 
77.0 
22.6 
0.4 
     197 
       57  
        0                             
 
77.6 
22.4 
0
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4.3 Clinical characteristics of participants 
Participants were on therapy for an average of 43±27 months but the females’ had been on 
therapy for a longer period (46.8±10.4) compared with the males (38.9±18.6) (Table) 4.1. Most 
respondents were on Combipak
R 
(40.8%) or Truvada
R
 regimens (32.3%); using a twice-daily-
regimen (85.9%) with 2-4 pills daily (80.5%). Less than half of all participants (48%) 
experienced side effects with their medications. Most participants (80.3%) had undetectable viral 
load (<400 copies/ l
3
); significantly more female (66.5%) than male (43.5%) participants’ 
achieved a CD4 count above 350 copies/ l
3
 (p=<0.001). 
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Table 4.2 Clinical characteristics of participants 
Clinical characteristics TOTAL 
n             % 
Female 
n             % 
Male      
 
n               % 
P 
Months on therapy      0.03* 
12 - 24 61           12.2 45 17.8 16 24.7           
25 - 36 98           19.5 42 16.6 56 22.7  
37 - 48 118         23.5 69 27.3 49 19.8  
>48 178         35.4 97 38.3 81             32.8  
Regimen      0.200 
Combivir
R
 56          11.4 17 6.7 39 15.7  
Combipak
R
 201        40.8 116 45.7 85 34.3  
Triomune
R
 31           6.3 18 7.1 13 5.2  
Truvada
R
 159        32.3 80 31.5 79 31.9  
TDF/3TC/LPV/r 46           9.2 19 7.5 27 10.9  
Frequency of dosing                                                                                                                   <0.001* 
Once daily 71           14.1  10 3.9 61 24.6  
Twice daily 431         85.9 244 96.1 187 75.4  
Daily pill burden                                                                                                                     <0.044* 
2 - 4 404        80.5 207 81.5 197 79.4  
5 -7 93          18.5 44 17.3 49 19.8  
>8   5            1.0 3 1.2 2 0.8  
Experienced side effects 241          48 119 46.7 132 53.6 0.72 
CD4 - count       <0.001* 
<350 225      44.8 85 33.5 140 56.5    
>350 277      55.2 169 66.5 108 43.5  
Viral load      0.126 
<400 403      80.3 196 77.2 207 83.5  
400 - 999 26        5.2 12 4.7 14 5.6  
1000-3000 22        4.3 15 5.9 7 2.8  
>3000 51        10.2 31 12.2 20 8.1  
 
* Statistically significant 
 
4.4 Behavioral characteristics of participants 
Most participants (95%) have disclosed their HIV status to family members (spouse, children or 
close relative) (90.4%), close friends (8.8%) or a religious leader (0.8%) (Fig 4.2). Almost all the 
participants (99.6%) knew the correct doses of prescribed medications. Similarly, 99.6% knew 
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the correct frequencies of administration (p=0.324) and 95.0 % knew the correct schedules of 
administration (p=0.236) (Table 4.3). 
 
Table 4.3: Behavioral characteristics of participants  
Behavioural 
Characteristic 
Total 
n                % 
Female 
n               % 
Male 
n                % 
p 
HIV disclosure 477 95.0 248 97.6 239 96.4 0.258 
 
Knowledge of correct dose 500 99.6 253 99.6 247 99.6 0.37 
 
Knowledge of correct 
frequency 
 
500 99.6 253 99.6 247 99.6 0.324 
Knowledge of correct 
schedule 
477 95.0 239 94.1 238 96.0 0.236 
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Figure 4.2 Targets of HIV disclosure 
 
4.5 Adherence  
The current study found that 95.0% of participants did not a miss a dose of their medication in 
the past 3 days while 99.6% took the correct doses of medication in the past 3 days. Also, 99.6% 
and 95.0% took their medications at the correct frequencies and on schedule in the past 3 days 
respectively. Total adherence – defined as taking 95–100% of prescribed medication in correct 
doses, at the correct frequencies and correct schedule during the previous three days - was only 
53.6% (p=<0.001). Significantly more male than female participants had total correct adherence 
over the previous three days (56.9% vs 43.1%; p=<0.001). Correct adherence based on 
prescription refill count over a period of 360 days was 62.5% (Table 4.3). 
 
 
  
1% 
90% 
9% 
Religious Leader
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Close Friend
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Table 4.4: Self-reported and prescription adherence  
Adherence  Total 
n                  % 
Female 
n                    % 
Male 
n                  % 
P 
Self-report over past 3 days      
Not missing a dose 477 95.0 238 93.7 239 96.4 0.169 
 
Correct dose 500 99.6 253 99.6 247 99.6 0.37 
 
Correct frequency 500 99.6 253 99.6 247 99.6 0.324 
 
Correct schedule 477 95.0 239 94.1 238 96.0 0.236 
 
Total correct adherence 269 53.6 116 45.7 153 61.7 <0.001 
 
Prescription refill count 
over 360 days 
 
314 
 
62.5 
 
163 
 
64.2 
 
151 
 
60.9 
 
0.447 
 
 
Barriers to adherence to ART 
The reasons for not adhering to prescribed medication among the participants (n= 25) that missed 
a dose of prescribed medication in the past 3 days were assessed. The study found that, 43% of 
participants missed a dose because they forgot to take their medication and, 21% said they 
travelled away from their homes, which was the reason for missing their medications. Similarly, 
16% of participants said they ran out of medication, 13% were busy at work, 5% lacked food and 
2% had their medication snatched by armed robbers (Figure 4.3). Thus, the psychosocial factors 
of forgetfulness, and travelling away from home and the structural problem of running out of 
medication were the common barriers to ART. 
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Figure 4.3 Reasons for missing doses  
 
Facilitators of adherence to ART 
The reasons for adhering to the prescribed medication were evaluated among the participants 
(n=477) who did not miss a dose of their medication in the past 3 days. The participants said they 
were motivated to take their medication because their “health condition improved (40%)”; and 
they “desired to live” (30.0%), had “family support” (22.0%) and “support group” (8.0%) 
(Figures 4.4).  
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Figure 4.4 Reasons for not missing doses  
 
4.6 Health system factors 
Drug availability 
Most participants (99.6%) were given all the prescribed ARV medication.  
 
Distance travelled, travel cost and time spent in the clinic 
Participants spent on average 100 minutes (IQR: 40 – 180 minutes) to travel to the study center 
(Figure 4.5). The median traveling cost to the clinic was N500 (IQR: N250- 900 for females and 
N250- N1000 for males; corresponding to a total IQR of 250-1000) (Figure 4.6).  Female 
respondents spend a median of 260 minutes (IQR = 200-340) in the clinic while the males spend 
a median of 300 minutes (IQR: 240-380) (Figure 4.7).  
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Figure 4.5 Distance travelled to ART clinic  
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Figure 4.6 Travel cost to ART clinic  
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Figure 4.7 Time spent in ART clinic 
 
4.7 Factors associated with adherence 
A positively statistically significant association was found between adherence and age; adults 
that were 30 years or less were 2.5 times more likely to adhere to their medications compared 
with those that were more than 30 years (OR = 2.5; 95% CI = 1.26-4.61; p = 0.023). The study 
also found a strong statistically significant positive association between adherence and viral load. 
Participants with viral loads of <400 copies/ l
3 
were 7 times more likely to adhere to their 
medication than those with a viral load >400 copies/ l
3 
(OR = 6.6; 95% CI = 1.6- 11.07; p = 
0.001). However, no statically significant association was found between adherence and marital 
status (p = 0.111); education (p = 0.331) and occupation (p= 0.147). Similarly, no significant 
 
 
 
 
 81 | P a g e  
 
association was between adherence and CD4 count (p=0.281), second line regimen (p=0.466) 
and pill burden (p=0.320) as well as experiencing side effects (p=0.372). Also, the distance that 
participants travelled to the ART Clinic to access treatment (p=0.460), the cost of travel to the 
clinic (p=0.102) as well as the time they spend in the clinic (p=0.210) to receive drugs were not 
significantly associated with adherence (Table 4.5). 
 .  
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Table 4.5 Factors associated with adherence over previous 3 days 
Variable Optimal 
Adherence  
Suboptimal 
Adherence  
Odd ratio  
(95% CI) 
P-value 
Age (in years) 
   > 30  
   ≤30  
 
239 
30 
 
177 
56 
 
Ref 
2.5 (1.26-4.61) 
 
 
0.023* 
Marital Status 
Ever Married 
Single 
(Widow/Divorce/Separated 
 
214 
55 
 
187 
46 
 
Ref 
0.9 (0.26-2.19) 
 
 
0.111 
Education 
None/Informal 
Formal 
 
28 
241 
 
22 
211 
 
Ref 
1.1 (0.31-5.14) 
 
 
0.331 
Occupation 
Formal Employment 
Informal Employment 
(unemployment) 
 
201 
 68 
 
 
183 
50 
 
Ref 
0.8 (0.28-3.84) 
 
 
0.147 
CD4 count 
<350 copies/ l
3  
 
>350 copies/ l
3  
 
 
112 
157 
 
113 
120 
 
Ref 
0.8 (0.13-1.62) 
 
 
0.281 
 
Viral load 
> 400  
 <400 
 
  
84 
185 
 
 
15 
218 
 
 
Ref 
6.6 (1.6- 11.07) 
 
 
0.001* 
Type of regimen 
1
st
 Line regimen 
2
nd
 Line regimen 
 
156 
113 
 
124 
109 
 
Ref 
1.2 (0.23-9.6) 
 
0.466 
Pill Burden 
>12 pills  
 <12 pills 
 
95 
174 
 
79 
154 
 
Ref 
1.0 (0.12-2.34) 
 
 
0.320 
Experienced side effects 
No 
Yes 
 
182 
87 
 
122 
111 
 
Ref 
1.9 (0.24-5.32) 
 
 
0.372 
Distance to clinic  
>100 minutes  
<100 minutes 
 
152 
117 
 
119 
114 
 
Ref 
1.2 (0.11-3.02) 
 
 
0.460 
Cost to clinic 
>N500.00  
<N500.00 
 
164 
105 
 
116 
117 
 
Ref 
1.6 (0.55-8.16) 
 
 
0.102 
Time in Clinic 
>260 minutes  
<260 minutes 
 
171 
98 
 
143 
90 
 
Ref 
1.1 (0.34-2.10) 
 
 
0.210 
         
*Statiscally significant 
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4.8 Summary 
Of the 502 participants, 254 were women and 248 men, with majority on ART for a 
mean of 43±27.1 months. Total adherence as measured by self-report was 53.6% (not 
missing dose (95.0%); correct dose (99.6%); correct frequency (99.6%), correct 
schedule (95.0%). However, prescription adherence was 62.5% and 80.30% of 
participants achieved virologic suppression at a level of <400 copies/ l
3
. Factors that 
constituted barriers to adherence were: forgot – 43%; travelled away from home – 
21%; ran out of medication – 16%; busy at work – 13%; lack of food – 5% and 
snatched by armed robbers – 2%. The adherence facilitators were: health condition 
improved – 40%; desire to live – 30%; family support – 22%; and support group – 
8%.  
 
Adherence was positively and significantly associated with age; adults ≤30 years 
were 2.5 more likely to adhere to their medications compared with those ≥30 years 
(OR = 2.5; 95% CI = 1.26-4.61; p = 0.023). Similarly, adherence was positively and 
significantly associated with viral load; participants with viral load of ≤400 
copies/ l
3  
were 7 times more likely to adhere to their regimens compared with those 
with viral load ≥400 copies/ l3  (OR = 6.6; 95% CI = 1.6- 11.07; p = 0.001).  No 
positive associations were found between adherence to ART and marital status (p= 
0.111); education (p= 0.331); occupation (p = 0.147); CD4 count (p=0.281); regimen 
type (p=0.466); pill burden (p= 0.320); experienced side effects (p =0.372); distance 
to clinic (p = 0.460); cost to clinic (p= 0.102) and time spent in the clinic (p= 0.210). 
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CHAPTER FIVE 
DISCUSSION 
5.1 Introduction 
Nigeria was facing HIV/AIDS crisis at the time this study was conducted in 2010. It was 
ranked third among the nations with the largest population of people living with 
HIV/AIDS in the world (FMOH, 2009). In 2010, a presidential directive to expand ART 
to remote areas was issued in an effort to stem the epidemic. This study set out to 
investigate adherence to antiretroviral therapy as well as analyse the factors that might 
constrain (barriers) and motivate (facilitators) adherence among adults who were on 
highly active anti-retroviral therapy in the Federal Capital Territory, Abuja, Nigeria, from 
2005 to 2010. The specific objectives of the study were to: measure the level of 
adherence to the ART; describe the socio-demographic characteristics of adult ART 
patients on the HAART; describe the clinical characteristics of adult ART patients and 
analyse the factors that constrain and facilitate ART adherence.  
 
5.2 The socio-demographic characteristics of adult ART patients on the HAART 
An equal proportion of women and men (50.6% vs 49.4%) participated in the study. This does 
not reflect the HIV prevalence across gender in Nigeria; 1.8 million women as against 1.3 
million men were living with the HIV at the end of 2010 (FMOH, 2010). The reason for the 
uniformity in the proportions of men and women in the current study may be due to how the 
participants were selected for the interview. The study devised a strategy that allowed an equal 
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number of men and women to be included in the study population. This was done to increase the 
internal validity of the study as well as enable a valid comparison between the characteristics of 
men and women. 
 
A vast majority of participants (82.2%) were older adults (above 30 years) with only a few 
(17.1%) younger adults (30 years or less). It is difficult to use the predominance of older people 
in this study to argue for a generational shift in the burden of HIV in sub-Saharan Africa where, 
younger adults are still the worst victims of HIV/AIDS (UNAIDS, 2008). The current study 
excluded younger persons less than 18 years, and the proportion of younger males and females 
who were less than 21 years was very small (0.8%); this may explain the reason for the low 
proportion of younger people in the study. However, it is important to high light the fact that it is 
the younger adults (≤30 years) that were 2.5 times more likely to adhere to their medications 
compared with the older adults (OR = 2.5; 95% CI: 1.26-4.6). This finding is not consistent with 
the Los Angeles study  that found older subjects to be three times more likely to be good 
adherers than the younger subjects (OR = 3.1, 95% CI: 1.40-6.76  ) (Hinkin et al., 2004). The 
finding is not also consistent with a South Africa study where adolescents and young adults were 
found to have poor adherence and poor virologic outcomes than do adults (Nachega et al., 
2009a).  
 
There were more married men than women among the participants (68.1% men vs. 37.8% 
women). More female participants were single or widowed which is consistent with the current 
HIV prevalence in Nigeria: lower HIV prevalence (4.9%) was reported among married women 
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compared with women who were single (5.6%) while women who were divorced, separated or 
widowed were reported to have the highest prevalence rate (6.9%) (FMOH, 2010). 
Male participants had significantly higher education than the females which reflects the literacy 
level in Nigeria: more men than women go to school particularly in the north. The current study 
did not find statistically significant association between adherence and education, which agrees 
with the finding of Eldred and his team where higher education was not found to predict 
adherence to ART (Eldred et al., 1998).  
 
Most men had formal employments [private business which includes, artisans (automobile 
mechanic, furniture makers), business/traders, civil servants and professional executives] 
compared with women (84.2% vs. 68.9% for women). Female participants, on the other hand, 
were significantly more in the informal employment sector (household/domestic work, 
housekeeping and farming) (p=<0.001) compared with the men (18.9% vs. 9.7% for men). These 
findings are consistent with the labour market situation in Nigeria: women were higher in 
proportion (57%) in informal employment, but in the formal sectors, they accounted for only 
39% (Ogwumike, Alaba, Alaba, Alayande and Okojie, 2005). The current study did not find 
occupation (formal or informal) to be associated with adherence to ART. This contradicts the 
claim in some studies that economic support is directly related to the level of adherence to ART 
(Gordillo et al., 1999; WHO, 2006a). The Brazilian study (Pelotas, Southern Brazil), also found 
that no significant association existed between poverty and adherence which further strengthen 
the argument that poverty may not be a predictor of poor adherence to ART under every 
circumstance (Pinheiro, de Carvallo-Leite, Drachler and Silveira, 2002).  
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5.3 Clinical characteristics of adult ART patients 
Viral load 
A vast majority of participants (80.3%) who were adherent to their regimens at a level of ≥95%, 
achieved undetectable viral load level (< 400 copies/ l
3
). This finding is similar to the finding by 
Paterson et al. (2000) where 80% of patients with ≥95% adherence had undetectable viral load 
level. The current study also found a statistically significant and positive association between 
viral load and adherence to ART. This is consistent with the overwhelming conclusion that 
adherence to ART is associated with viral suppression (Paterson et al., 2000; Safren, 
Kumarasamy, Raminani, Solomon and Mayer, 2005).  
 
The positive and significant association between the reported adherence level and the 
corresponding virus load in the current study lent support to the reliability of the adherence 
assessment used in the current study. It also provides an insight into the quality of drugs at the 
treatment centre; the review of literature revealed that the type of drug and quality of drug 
contribute to viral suppression (Weiser et al., 2004; Maggiolo et al., 2005; Bangsberg et al., 
2007; Wainberg et al., 2007; Bangsberg et al., 2003; Harrigan et al., 2005; King et al., 2005). 
Thus, drugs with high quality will consequently suppress the viruses to undetectable viral load 
level even with suboptimal adherence (< 400 copies/ l
3
). Since the current study found a 
significant association between virologic suppression and adherence to ART despite the fact that 
only 53.6% of the participants had optimal adherence, it suggests that the virologic suppression 
reported in the curret study may be as a result of the quality of drugs or the type of drugs and 
other factors rather than adherence to ART itself. If this is the case, then the stocking of high 
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quality drugs as well as storing drugs at the recommended temperatures should be sustained at 
the treatment centre. 
 
CD4  
There were more participants with CD4 counts above 350 copies/ l
3
 compared with those with 
CD4 count of less than 350 copies/ l
3
 (55.2% vs 44.8%). This is a good development 
considering the fact achieving higher CD4 counts is one of the goals of ART. However, 
participants that were still having CD4 count less than 350 copies/ l
3
, despite being on treatment 
for twelf months may be struggling with immunological treatment failure since immunological 
treatment failure is assumed if there is a failure to achieve a CD4 cell count increase of 50 to 100 
cells/ l
3 
per year (FMOH, 2007). The WHO recommends regimen switch from first line to 
second line regimens for participants with treatment failure (WHO, 2009) but the current study 
found that majority of the participants were still using first line regimens, which suggests that the 
treatment centre may not be reviewing and switching patients to second line regimens as it 
should be. The health providers must pursue with greater seriousness the review of treatment and 
possible regimen switch inorder to improve quality of care and adherence to ART. No 
statistically significant association was found between CD4 and adherence to the ART in the 
current study. In most studies however, adherence to ART has been found to be a predictor of 
high CD4 count (Paterson et al., 2000; Safren, Kumarasamy, Raminani, Solomon, and Mayer, 
2005). The reported lack of association between CD4 count and adherence in the current study 
could be as a result of several reasons including the way the study was designed, immune 
system, nutritional status and socio-economic status of the participants and drug resistance. 
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Nonetheless, achieving high CD4 count remains the goal of antiretroviral therapy which ART 
program implementers must strive to achieve. 
 
HIV status disclosure 
Disclosure of HIV status was very high (95%) and disclosure to the family alone accounted for 
90.0% (Table 4.3). This finding contradicts the general believe that people living with the HIV 
are not diposed to disclosing their HIV statuses due to the fear of stigmatization. Optimum 
adherence to ART has also been associated with the disclosure of HIV status on the ground that 
it promotes a strong internal commitment to treatment which leads to ART adherence (Reynolds 
et al., 2004). In the current study, suboptimal adherence has been reported among the 
participants; this questions the impact of HIV disclosure in improving adherence to ART. 
 
Months on therapy 
Majority of participants had been on therapy for a mean of 43±27.1 months. This finding 
supports two findings of the current study. First, it supports the high viral suppression reported in 
this study (80.3% participants had < 400 copies/ l
3
) because studies have shown that high viral 
suppression minimizes both morbidity and mortality and as a result, patients may live longer 
(Paterson et al., 2000). It also supports the participants’ claim that the treatment was improving 
their condition – the current study found that 43.0% of the participants gave “improvement in 
health condition” as the principal reason for adhering to their medications.  
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Treatment regimens 
Our study found no significant association between adherence and type of regimen (first line and 
second line). However, most respondents were using the Combipak
R 
(40.8%) and Truvada
R
 
based regimens (32.3%) which are classified as first line regimens under the Nigerian treatment 
guideline. Additionally, Combipak
R 
and Truvada
R
 are fixed dose combination of drugs and as 
such, only few pills are taken and they have manageable side effects with no food restriction. 
Medications with low pill burden, less side effects and frequency of dosing have been found to 
promote adherence to ART (Kleeberger, Phair, Strathdee, Detels, Kingsley and Jacobson, 2001; 
Eldred, Wu, Chaisson and Moore, 1998). They are usually preferred by clinicians and are the 
first treatment of choice according to studies (Bangalore, Kamalakkannan, Parkar and Messerli, 
2007). In the current study, high adherence rates were found when adherence was measured by 
dose taken, frequency and compliance to schedule of administration. Jean-Baptiste (2008) also 
found a high adherence rate when adherence was measured by dose taken among patients who 
were on fixed dose Triommune than among those on multiple drug regimens. It is likely 
therefore, that the dependence on the FDCs at the treatment centre as found out in the current 
study is the reason for the reported high adherence rates when adherence was measured by dose, 
frequency and schedule of administration. But “total adherence” was only 53.6%, suggesting a 
failure to comply with frequency and schedule, which indicates that as treatment failure occurs 
and patients are switched to second line regimens, which are much more complicated and 
difficult to take, maintaining high level of adherence may not be possible. 
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Side effects of regimen 
Majority of the participants (52.0%) did not experience side effects with their drugs and no 
significant association was found between adherence and the side effects of the ART drugs used 
in the current study. This is a strange finding because some studies have found that side effects 
of anti-retroviral drugs are predictors of poor adherence to ART (Ammassari et al., 2001b; 
Weiser et al., 2003; Machtinger and Bangsberg, 2005; Weiser et al., 2003; Roberts, 2000; 
Pinheiro, de Carvallo-Leite, Drachler and Silveira, 2002; Popa-Lissenanu et al., 2005; Mills et 
al., 2006a; Uzochukwu et al., 2008). The reason for the lack of association between adherence and 
side effects in the current study may be related to the drug regimen the participants were using. As shown 
earlier, the regimens most participants were using have less and manageable side effects that may 
disappear within 4 months on therapy (Flexner, 2006). Since the participants had been on therapy 
for at least 43 months, it is likely that the side effects they experienced at the beginning of the 
therapy have disappeared at the time the current study was conducted. It is also argued that 
patients with HIV tolerate side effects better than patients with less severe chronic diseases, such 
as hypertension and diabetes mellitus (Mehta, Moore and Graham, 1997), because they are more 
aware of the adverse outcomes associated with poor adherence (Paterson et al., 2000). The 
studied population has benefitted from the formal counseling reported in the current study and as 
such, they were more likely to be aware of the danger of poor adherence and have developed 
tolerance to the side effects. 
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Pill burden and frequency of administration 
Most participants (80.5%) were using twice-a-day regimen with low pill burden and frequency 
of administration but no positive significant association was found between pill burden and 
adherence to ART by the current study. This is consistent with the finding of Fong et al. (2003); 
pill burden, dosing frequency and dietary restriction did not predict a poorer drug adherence 
among Chinese patients who took more than 10 pills per day and thrice-a-day. It is noted that 
Government collaboration with PEPFAR in the ART program made it possible for fixed dose 
combination drugs with less pill burden to be supplied to the study center.  
 
5.4 The health system factors 
Drug availability at the study center 
Almost all the participants (99.6%) were given all the antiretroviral medications prescribed; 
suggesting that the study center was adequately stocked with drugs. The World Health 
Organization recommends 4 regimens (AZT+3TC+EFV; AZT+3TC+NVP; TDF+3TC or 
FTC+EFV and TDF+3TC or FTC+NVP) for starting ART in ART-naïve individuals (WHO, 
2009) but five different regimens were physically sighted at the time of the study which further 
indicates that the treatment centre was adequately stocked with drugs. Ideally, the constant 
availability of drugs at the treatment centre should lead to high adherence among the participants 
as drug availability has been associated with ART adherence (Mills et al., 2006b).  However, 
suboptimal adherence has been reported in the current study which reflects the thinking that 
sustaining high adherence to ART goes beyond having constant availability of products. Health 
providers must ensure that patients are properly counselled on the use of ART drugs which are 
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complicated and difficult to use. But this seems to be lacking at the treatment centre with the 
finding that only 53.6% of the participants were taking their drugs correctly with respect to 
dosing, frequency and schedule of administration. 
 
Distance to clinic 
Both male and female participants spend an average of 100 minutes (IQR: 40 – 200 minutes) to 
get to the clinic. Since most of the participants claimed they travelled by automobiles, a journey 
of 100 minutes (above 1.7 hours) is definitely a long distance.  In Botswana, a similar finding by 
Weiser et al. (2003) showed that patients lived 800 to 1000km away from the clinic and had to 
travel that distance monthly. Citing treatment centres in Hospitals located in townships while 
majority of patients live in rural areas many kilometres away, is one reason patients have to 
travel long distances to access treatment. Also, the fear of stigmatization from the community 
might also force individuals to select treatment centres that are far away from them. A few 
studies actually show that stigma and discrimination forces HIV infected patients to engage in 
high-risk behaviour such as unsafe sex and travelling longer distances to access treatment to hide 
their HIV statuses (Qwanaet al., 2000).  
 
Cost to clinic 
Both men and women paid on average, N500.00 (IQR for females and males: N250.00- N900.00 
and N 250.00- N1000.00 respectively) to get to the clinic.  However, 75% of male participants 
paid more than the females’ with as much as N1000.00).  No study has been done to establish the 
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personal cost of accessing ART in Nigeria, but considering the high rate of unemployment 
(4.9%) with 70% of the population living below the poverty line (CIA, 2008), paying N1000 just 
to go to clinic is too expensive. It is difficult to explain why the men were paying more money 
on transportation than the women; it is likely that stigmatization might be the reason as male 
participants may select to pay more money and travel longer distances to access treatment to hide 
their health condition. This assumption is strengthened by the fact that stigmatization was 
reported to be a serious problem among patients on the ART in South East, Nigeria (Uzochukwu 
et al., 2008).  
 
Time in the clinic 
The current study found that participants spend longer times in the clinic but women spend less 
time than men (a median of 260 minutes for females and 300 minutes for males). Similar studies 
in Botswana, Tanzania and Uganda found that a patient spend on an average of up to five hours 
waiting for consultation and medication (WHO, 2006b). Again, it is difficult to explain why the 
women spend less time than the men. But if men were travelling longer distances to arrive at the 
clinic late when the health workers were tired, that might affect the length of time they have to 
wait to be attended to. The study centre keeps the “first come, first serve” rule, i.e., those who 
come to the clinic first are served first and those who came late are served later. 
 
The current study did not find statistically significant positive associations between distance to 
clinic, cost to clinic and time in clinic with adherence to ART. However, the lack of association 
does not in any way under rate the vital role that these factors play in constraining or motivating 
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adherence to ART. Studies have recommended the suggestions below for addressing long 
distance, high cost and long waiting time in the clinic (INRUD-IAA et al., 2008). However, it 
should be noted that the effectiveness of these recommendations has not been tested and as such, 
caution is required. 
.  
Distance to the clinic could be reduced by: 
 providing patients with drugs for longer  time and arrange for better laboratory services 
so  that patients will not have to return so frequently 
 Bring services closer to the patients, and use peripheral community-based health workers 
for drug distribution 
  Give direct economic support and/or initiate income-generating programs 
 Home delivery of drugs can also reduce distance and the cost of transportation; and some 
studies have shown that the use of home delivery of drugs appears to be effective in 
increasing adherence and decreasing viral loads. 
 
Waiting times in clinics can be reduced by: 
• Arranging more efficient flow of patients between different providers and stations appointment    
schedule, 
• Splitting appointments into two half days, 
• Keeping clinics open additional days, 
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• Increase number of staff 
• Decentralize services to the communities 
A multi-centre study in Uganda and Kenya recommended the deployment of the above 
strategies, although there are no evidence to prove their effectiveness on reducing the waiting 
time in clinic and subsequently improving adherence to the ART (INRUD-IAA et al., 2008). 
 
5.5 Behavioral characteristics  
Knowledge of the ARV regimen 
Most participants had knowledge of their antiretroviral medications – 99.6% knew the correct 
dosages, 99.6% knew the correct frequencies and 95.0% knew the correct schedules of 
administration (Table 4.3). The study centre places high premium on counseling and education 
and this may account for the knowledge of drugs by the participants. First, patients must 
complete a counseling course and be issued a certificate before commencing treatment. Second, 
patients compulsorily attend a health talk each time they visit the clinic to refill their 
prescriptions. The pharmacists and clinicians also provide some form of counseling to the 
patients as they attend to them. A high level of adherence is therefore expected at the treatment 
centre considering the fact that knowledge of drugs and patient counseling are associated with 
optimum adherence (Simoni et al., 2006). However, the current study found a suboptimal 
adherence level, which does not support the knowledge of drugs by the participants. There is 
need to explore the factors that may be responsible for the suboptimal adherence to ART among 
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the participants despite having correct knowledge of dosing, frequency and schedule of drug 
administration. 
 
5.6 Adherence to the ART in the FCT 
Adherence by patient self-report 
Adherence was measured using five different criteria: not missing dose, taking the correct dose, 
complying with the correct frequency, complying with the correct schedule and effective 
adherence. On the basis of not missing a dose in the past 3 days, adherence was 95.0%. 
However, on the basis of taking the correct dose, and complying with the correct frequencies and 
schedules of administration, adherence rates were 99.6%, 99.6% and 95.0% respectively. But 
when adherence was measured comprehensively (total adherence) by looking at correct dosing, 
frequency and schedule at the same time, the level dropped to only 53.6%, and significantly 
more men than women were adherent. Eighty point three percent (80.3%) of the participants who 
adhered to their drugs at a level of ≥95.0% had undetectable viral load level (Table 4.5). 
Prescription refill adherence was only 62.5%.  
 
 
The above findings on the rates of adherence to ART make a strong case on seven important 
issues worth considering. These are: the reported suboptimal adherence rate by the current study; 
the reported high level of adherence in sub-Saharan Africa; suboptimal adherence with high viral 
suppression; different rates of adherence between men and women; validation of self-reported 
adherence information; and the measurement of adherence using the self-reported measure. 
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The reported suboptimal adherence rate by the current study 
The 53.6% adherence rate for the FCT is suboptimal. Yet, disclosure of HIV status, constant 
availability of drugs and user friendly ARV regimens which have been shown to promote 
adherence to ART (Nachegaet al., 2010; da Salviera et al., 2003) were reported at the study 
center by the current study. For instance, 95% participants disclosed their HIV status (Table 4.3), 
99.6% had all the prescribed ARVs and most participants were using ARV regimen that had no 
dietary restriction and could be taken once or twice daily (Table 4.2). Why does suboptimal 
adherence persist in the midst of factors that ordinarily should have improved adherence to 
ART? 
 
The current study did not explore the causes of suboptimal adherence; this is an area for future 
research. However, the failure to follow specific instruction around timing of taking medication 
may explain the suboptimal adherence level. As indicated above, adherence level was very high 
(95.0%) when measured by doses taken but when timing (frequency and scheduling) was 
considered together with the doses taken, the level went down to barely 53.6%. Essentially, 
patients thought they were adherent by simply taking the medication, but in truth it was only 
partial adherence because taking drugs off schedule does not allow adequate concentration of the 
drug in the blood and effective viral suppression cannot be guaranteed (Castleman, Seumo-Fosso 
and Cogill, 2003).  
 
The suboptimal adherence level suggests that the adherence strategies that have been employed 
to improve adherence at the treatment center, which include treatment preparation and 
 
 
 
 
 99 | P a g e  
 
counseling are not working as they should. There is need to develop an adherence model that 
would address taking medication on schedule among other factors. Future research must focus on 
this area so as to improve adherence to ART in the FCT. 
 
 The reported high adherence level in sub-Saharan Africa  
Several studies in sub-Saharan Africa have reported very high adherence rates. For instance, a 
study in greater Cape Town reported a 93.5% adherence with 70.9% viral suppression (Orrell, 
Bangsberg, Badri and Wood, 2003b).  The review of adherence studies from sub-Saharan Africa 
and North America by Mills et al. (2006b) also reported a higher pooled estimate of adherence in 
sub-Saharan Africa than in North America (77% vs 55%). Also, Nachega et al reported a median 
adherence level of more than 95% during a 2-year follow-up of patients from Cape Town, South 
Africa (Nachega et al., 2009b).  However, the current study reported only 53.6% adherence rate 
which is a significant difference compared with the rates reported in other adherence studies.  
 
Gill et al had argued that the high level of adherence to ART reported in sub-Saharan Africa is as 
a result of researchers using the self-reporting adherence measure (which overestimate 
adherence); taking smaller sample sizes; including participants that have been on therapy for 
shorter periods and using only one measure of adherence (e.g., number of pills taken) to evaluate 
adherence to ART (Gill et al., 2005). This argument is corroborated by Fong and his team; they 
reported a high adherence rate (80.7%) among Chinese patients on HAART but admitted that 
they did not measure adherence comprehensively, which according to them; led to the high 
adherence rate (Fong et al., 2003). Similarly, Jean-Baptiste found that, adherence was very high 
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(99.9%) when measured by proportion of pills taken but dropped to only 73.0% when it was 
measured comprehensively (Jean-Baptiste, 2008). The current study is reporting a suboptimal 
adherence rate because adherence was measured comprehensively. If adherence had been 
measured by doses taken or not taken as done in other studies, the adherence level would have 
been 95.0% as stated above. The finding of the current study strongly questions the reported high 
adherence rates in Africa.Gill et al. (2005).  
 
Suboptimal adherence with high viral suppression  
The correlation between adherence and virologic suppression cannot be overstated. Studies have 
shown that with increase in the level of adherence, there is a corresponding increase in virologic 
suppression. For instance, a 95% adherence rate results in a virologic suppression success of 
more than 80%, while the success rate drops to 60% in patients with 80-94.9% adherences 
(Kleeber, Phair, Strathdee, Detels, Kingsley and Jacobson, 2001). In another study, it was found 
that as the level of adherence dropped to 90%, only 78% of patients could achieve UDVL 
(Arnstenet al., 2001). In the current study, the 53.6% adherence level is disproportionately lower 
than the 80.3% virologic suppression. In other word, suboptimal adherence persists in the midst 
of high viral suppression. One possible explanation for this is that adherence alone is not the only 
factor that contributes to virologic suppression eventhough; it is the principlal factor according to 
studies. Studies have shown that nutritional and  immunal status of patients, the viral genome, 
socio-economic status, length of time on medication and the type of regimen can also affect 
virologic suppression (Weiser et al., 2004; Maggiolo et al., 2005; Bangsberg et al., 2007; 
Wainberg et al., 2007; Bangsberg et al., 2004; Harrigan et al., 2005; King et al., 2005). It is 
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likely that these factors were responsible for the high viral suppression rather than adherence 
itself in the current study. If this is the case, achieving high level of adherence should not be the 
only focus of ART rather; all adherence determinants must be identified and addressed.  
 
 
Different rates of adherence between men and women  
The association between gender and adherence to ART has been a contentious problem. While 
several studies have failed to show a significant association between gender and antiretroviral 
adherence (Eldred et al., 1998; Moatti et al., 2000; Wagner et al., 2002; Carrieri et al., 2003; 
Holzemer et al., 1999; Bouhnik et al., 2002; Golin et al., 2002; Gordilo et al., 1999; Chesney et 
al., 2000; Paterson et al., 2000), a large body of studies have shown that women are less adherent 
than men (Arnsten et al., 2002; Turner et al., 2003; Altice et al., 2001; Delgado et al., 2003; 
Wenger et al., 1999; Montessori et al., 2000; Abriola et al., 2000; Arabe et al., 1998; Montaner 
et al., 2000). It is argued that most studies that found no association between gender and 
adherence were limited either by small numbers of women or by the use of self-report, which has 
been shown to overestimate adherence (Wagner, 2002). The current study included an equal 
proportion of men and women in the studied population and significantly more men than women 
were adherent (56.9% vs 43.1%; p=<0.001). This finding lent support to the conclusion that 
when it comes to adherence, it is the men that are getting it. But this is very strange because 
adherence to ART requires very stringent discipline with time keeping; the chaotic lifestyle 
associated with the behavior of most men cannot accomondate it. On the other hand, women are 
culturally more patient and would under normal circumstance want to live longer to take care of 
their children which is a strong motivation for adherence to ART. It is likely that the women in 
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the current study were more honest in providing adherence information with their experiences 
with the drugs than the men and that may explain why a fewer proportion were adherent 
compared to the men. Whatever is the reason, there is need to explore the factors that account for 
the significant difference in adherence to ART across gender. 
 
 Validation of self-reported adherence information 
Evidence abound that the self-reported adherence measure is sensitive to desirability bias and 
adherence information could be exaggerated. Thus, validation of self-reported adherence 
information with viral load test has been recommended (Gill et al., 2005). In the current study, 
the non-viral validated adherence rate was in the range of 95.0% to 99.6%, while the viral load 
validated adherence was 80.3% (Table 4.5). This finding validates the adherence information 
provided by the participants. It also questioned the generally accepted claim that patients who 
struggle with adherence would be unwilling or unable to admit to non-adherence to health care 
professionals. However, it has been recommended that researchers evaluating adherence through 
the self-reported measure should endeavour to validate self-reported adherence information with 
viral load test (Gill et al., 2005). 
 
 
Measurement of adherence using the self-report measure 
The self-report measure of adherence has been shown to generate different levels of adherence to 
ART (Jean-Baptiste, 2008). When this method was used in the current study, different levels of 
adherence were found with different adherence masures as stated above. This has confirmed that 
adherence level measured through self-reporting will vary depending on the criteria that are used. 
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Thus, to measure adherence comprehensively, critical criteria, like dose taking, frequency and 
schedule of drug administration must be considered. However, in most adherence studies in sub-
saharan Africa that used self-reporting, “pills missed” or “pills taken”, were the criteria 
frequently used to assess adherence level without considering whether the drugs were taken at 
the correct times or not (Jean-Baptiste, 2008). Frequently, if a patient says he/she did not miss a 
dose, it was assumed that the patient had taken the correct dose and maintained the correct 
frequency and schedule of administration. But the finding of the current study does not support 
this assumption; patients who may not be missing their doses of medication may not be taking 
them appropriately and this has serious consequences. A study conducted to evaluate the effect 
of taking medication at the correct frequency and correct schedule showed that patients who took 
their medicines off schedule or without the required food restrictions were not getting the full 
benefits of the medicine and were experiencing treatment failure (Castleman, Seumo-Fosso and 
Cogill, 2003). The current study therefore affirms that, assessing adherence by the self-reported 
measure is much more complex; future researchers should not limit themselves to using only the 
“doses taken” or “missed” as the basis of assessing adherence to the ART. We must change the 
way adherence to ART is evaluated using the self-reporting measure. 
 
Barriers to the ART 
No study has systematically investigated the barriers and facilitators of long-term adherence to 
ART in the Federal Capital Territory (FCT), Abuja, Nigeria. Elucidating the barriers and 
facilitators is critical if policy makers in the FCT and Nigeria are to identify pitfalls in current 
strategies that should be addressed while devising effective AIDS treatment programs. In the 
current study, “forgetfulness” (43%), “travelled away from homes” (21%), “ran out of 
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medication” (16%), “busy at work” (13%), “lack of food” (5%) and “medication snatched by 
armed robbers” (2%) were found to be barriers to adherence to the ART (Figure 4.7) 
 
Forgetfulness 
Forgetfulness (43%) was the major cause of poor adherence among the participants who reported 
missing at least a dose of their medication. Other studies have also found forgetfulness as a 
barrier to ART adherence (Roberts, 2000; Reynolds et al., 2004; Marais, 2006; Mills et al., 
2006a; WHO, 2006b; Dieckhaus and Odesina, 2007; Wang and Wu, 2007; Amberir et al., 2008; 
Thobias, 2008; Malangu, 2008).  
 
Interventions that have been designed to address forgetfulness have involved patient education, 
counseling and the use of external devices that prompt patient to take medications. A meta-
analysis of randomized controlled trials of clinic-based patient education and counseling found 
that participants who received education and counseling were significantly more likely (OR=1.5) 
to reach the optimal level of 95% adherence; and to have an undetectable viral load (OR-1.25) 
than those who were not offered such counseling (Simoni et al., 2006). The importance of 
counseling, over and above external reminders (as highlighted in the meta- analysis) was 
confirmed by a recent multi-center trial in the United States. This trial compared the effects of an 
electronic medication alarm system with those of "medication managers" —clinic staff who were 
given two days of training on how to conduct adherence counseling and how to help patients 
identify and overcome barriers to adherence. Medication managers were found to have 
significantly helped to increase the levels of optimal adherence, which was not the case for the 
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electronic medication alarms (Mannheimer et al., 2006). Thus, counseling can be deployed to 
address forgetfulness. However, the quality of counseling can be strengthened further by:  
• Fully evaluating patients’ motivation for treatment before starting the ART 
• Performing proper opportunistic infection (OI) screening, adverse drug reaction (ADR) and 
adherence monitoring 
• Training staff, including other support staff, in communication skills and adherence 
counselling. 
 
Emerging technologies, particularly the use of cellular telephone technology has also been 
advocated for addressing the problem of forgetfulness. The cellular phone approach is culturally 
relevant for telephone owners; in Nigeria, practically every adult has a cellular telephone. The 
telephone is largely confidential, (particularly if text messages are used), is not affected by 
distance, and can be uniquely modified to meet patients’ individual education or lifestyle needs. 
The telephone strategy was particularly useful during stock shortages during the political 
violence in Kenya in 2008 (Nachega et al., 2010). To minimize the suboptimal adherence 
reported in the current study, the use of medication managers, counseling and the telephone 
strategy are all recommended. 
 
Travelling away from home and busy with work 
Travelling away from home (21%) and busy at work (13%) were identified as barriers to ART 
adherence in the current study. Stout et al. (2004) also found travelling and being busy with work 
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as a barrier to the ART. Over busy patients are likely to forget their medication behind or they 
may carry them along but forget to take them. Thus, patients’ counseling as recommended above 
under forgetfulness can be used to address these factors. 
 
Running out of medication 
Sixteen per cent (16%) of participants gave running out of medication as their barriers to 
adherence. Running out of medication has been reported as an adherence barrier to the ART in 
sub-Saharan Africa. For instance, a cohort analysis from Uganda found that initially excellent 
adherence declined over one year as patients experienced pharmacy stock-outs (Oyugi et al., 
2007). In South East Nigeria, another adherence study found running out of drugs as an 
adherence barrier (Uzochukwu et al., 2008). Similarly, Mills et al. (2006b) indicated that the 
most important and frequent factors reported to negatively impact adherence in developing 
countries are cost of drugs (Weiser et al., 2003; Laniece et al., 2003) and structural barriers, such 
as pharmacy stock-outs, among others (Oyugi et al., 2007).  
 
It is not clear why the participants at the study center should experience “running out of 
medication” considering the constant availability of drugs reported in the current study. It is 
likely that economic factors constrained them from travelling to the study center to access drugs 
because; participants paid a median of N500.00 to travel to the clinic according to the current 
study. There might also be problems with the logistics of drug distribution and this can create 
temporary drug stock-outs, leading to participants running out of their medications. To address 
all these, home delivery of drugs or giving sufficient quantities of drugs e.g., three months’ 
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supply may address the problem if poverty was the problem. If drug distribution was the 
problem, facility staff responsible for requesting drugs from the central store may need to 
improve on inventory management generally. For instance, the pull system of drug distribution 
should be used instead of the push system. The pull system is a system of drug distribution that 
depends on using consumption data to generate drug requisition for re-stocking. The system 
delivers only what is needed and as such, it addresses under-stocking which often leads to drug 
stock-out. Practical steps that may be deployed to address the problem of running out of 
medication may include: 
• Assigning responsibility for drug supply to one person who is supported by the management 
• Supporting stable donorship and efforts to reduce costs for OI medicines or make arrangements 
for completely free medicines 
• Stabilizing delivery of drugs, clarify the question of responsibility when problems arise with 
drug delivery and service 
 
Lack of food 
Only a small proportion of participants (2%) complained of lack of food as a barrier to adherence 
to the ART in the current study. However, lack of food was found to be a very serious barrier to 
the ART in Uganda where food shortage was a serious concern for the majority of patients 
(INRUD-IAA et al., 2008). The experience of an increased appetite when on the ART presented 
yet an even greater barrier to adherence and was reported as a reason for patients to stop the 
treatment (INRUD-IAA et al., 2008). 
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Food distributions programs have been used to address lack of food, but sustaining such 
programs are quite challenging. A study in Uganda found that the food distribution program that 
was deployed to address the persistent food shortage later collapsed as a result of lack of funds 
(INRUD-IAA et al., 2008). 
 
As policy makers devise strategies to address the identified barriers in the current study, much 
emphasis should be focused on the psycho-social factors (forgetfulness, travelling away from 
home and being busy with work), because these factors are largely responsible for poor 
adherence among the non-adherent participants. However, the socio-economic and structural 
factors (running out of medications) should be addressed if only to minimize the poor adherence 
level reported in the current study. 
 
Facilitators of adherence to the ART 
Improvement in health condition 
Improvement in health condition does not support the suboptimal adherence reported in the 
current study, because suboptimal adherence predicts poor virologic suppression and poor 
improvement in health condition (Paterson et al., 2000). Nevertheless, the efficacy of medication 
or the type of medication may have led to the improvement in health condition. For instance, the 
combination of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and boosted protease 
inhibitor-based cART can achieve virologic suppression at a moderate adherence of 70 – 90% 
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(Nachega et al., 2007; Shutter et al., 2007; Martin et al., 2008). If this was the case, then the 
procurement of efficacious and quality drugs would be an important step towards sustaining 
adherence to ART at the study center. Storage of drugs at the recommended temperatures would 
also improve the efficacy of drugs, which the study center must pursue. However, patients’ 
confidence on the efficacy of medication is very important. A practical strategy that may 
enhance patients’ confidence on medication is to have the ART programs take more active part 
in community life through support groups and enhance sensitization through people living with 
HIV/AIDS (PLWHA) who can attest to benefit of life-saving drugs. 
 
Desire to live 
The desire to live can be promoted by counseling and education. Anxiety and depression are 
common among persons living with HIV/AIDS, with a prevalence of nearly 50% in a U.S. 
screening sample of 2,864 HIV infected persons (Ammassari et al., 2004a). When people are 
presented with the HIV infection, they may suffer psychological depression leading to low 
morale, loss of interest in life and the desire to live (Ammassari et al., 2004a).  But these can be 
reversed with effective counseling particularly when the benefits of adherence to the ART are 
expounded and patients realize that they can do what others are doing and may even live longer 
by simply adhering to their medications. The study center, as found out in the current study, 
provides integrated counseling and routine patient education on each clinic visit. Patients were 
not started on the ARV medications until they have completed the compulsory counseling 
education and a certificate of completion issued. This practice is most likely contributing to the 
participants’ desire to live and therefor, should be sustained and strengthened.  
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Support group 
Providing support from the immediate family of the participants as well as from social 
organizations like the support group network, were promoters of adherence to the ART 
according to the current study. In other studies, consistent support from the family was 
found to facilitate adherence to the ART (Chesney et al., 2000; Bearman and La Greca, 
2002; Simoni, Frick, Lochkart and Liebovitz, 2002; Attawell and Mundy, 2003; Hofer, 
Schechter and Harrison, 2004; Kagee, Le Roux and Dick, 2007). According to Attawell 
and Mundy (2003), a spouse support and support groups play a crucial role in HIV 
medication adherence. 
 
The role that family support and the support group system have played in promoting 
adherence to the ARVs have been reported in some studies (Chesney et al., 2000; 
Bearman and La Greca, 2002; Simoni, Frick, Lochkart and Liebovitz, 2002; Attawell and 
Mundy, 2003; Hofer, Schechter and Harrison, 2004; Kagee, Le Roux and Dick, 2007). 
Therefore, there is need to strengthen community linkages as this will strengthen the 
support group system. The following practical strategies are recommended: 
• Use relevant number of peripheral trained community-based health workers, preferably those 
with experience of living with HIV/AIDS 
• Collect information on patients’ health status and adherence, thus detecting defaulters, which 
are communicated by cell-phones back to the clinics 
• Use community-based health workers for support in a home-based model on HIV/AIDS care. 
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5.7 Limitations of the study 
The cross sectional design 
As stated above, the cross sectional design was adopted for the current study because it is the 
best design for describing the scope of problems in operational/health system research (Grimes 
and Schuz, 2002). However, a cross sectional design does not allow causal relationships to be 
established, unlike cohort or case control studies (Grimes and Schuz, 2002). For instance, the 
cause of psycho-social factors as barriers to adherence to the ART in the current study cannot be 
clearly stated because of this limitation. As a result, program implementers may have to identify 
the causes through further studies before addressing them (Grimes and Schuz, 2002). 
 
The quantitative data collection technique  
A structured questionnaire was used for the data collection. Thus, participants had no chance of 
expressing their opinions on very critical matters, which would have shed more light, for 
instance, on the factors associated with adherence. It means that ART program implementers 
who are interested in addressing the adherence determinants constraining and facilitating 
adherence to the ART may do a qualitative study to have a comprehensive and in-depth 
understanding of the adherence determinants reported in this study. Addressing problems without 
a comprehensive understanding of the problem is superficial, which strongly supports the need 
for a qualitative study. 
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The adherence measures: self-report and prescription refill 
The self-reported and prescription refill adherence measures were adopted for evaluating the 
scope of adherence to the ART. Both measures have been shown to correlate with viral 
suppression and optimal clinical outcome (Nieukerk and Oort, 2005) and have been used in 
several studies to measure adherence to the ART (Mills et al., 2006b). However, the two 
measures are not totally free from weaknesses that may affect the validity and overall result 
findings of a study.  
 
The self-report measure is sensitive to desirability bias since participants are more likely to 
provide information that they consider socially desirable rather than being totally honest. Over 
estimation of adherence information leading to inflated adherence rates has therefore been linked 
to the self-report measure (Chesney, 2006; Gill et al., 2005). The prescription refill measure is 
not sensitive to desirability bias; however, recorded data may be incomplete and may provide 
incomplete information that is out-dated. The quality of information may be compromised, 
because the information was recorded by different people for different purposes other than 
research (Araoye, 2003). Similarly, transcription errors where data clerks enter data incorrectly, 
e.g., recording 0 instead of 10 are common with retrospective data. It has also been suggested 
that retrospective data usually need to be updated before they are used because certain 
information recorded in the past may have changed at the time of the study (WHO, 2004). The 
tear and wear of the papers where the data were entered initially may lead to incompleteness of 
the original information, which may also require updating.  
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In the current study, much effort was invested in updating the pharmacy records.  For instance, 
participants who were considered lost to follow up (LTFUP) in which case, they did not visit the 
clinic to refill their prescriptions for the past 4 months but suddenly showed up during the data 
collection period, were excluded for having incomplete prescription data. Despite this effort, it is 
impossible to have ruled out all the errors associated with using retrospective data and therefore, 
the prescription refill adherence rate reported in this study must be viewed within the confine of 
these errors. 
 
 The use of a single site 
Conducting the study at one site rather than at multiple sites within the territory, suggests that the 
finding of the study may only be generalized to the treatment centers that are similar to the 
University of Abuja Teaching Hospital, e.g., the PEPFAR supported public health facilities, 
which constituted over 90% of health facilities. However, caution is required in generalizing 
findings to treatment centers that are totally different from the University of Abuja Teaching 
Hospital, e.g., the private hospitals without the PEPFAR support and treatment centers located in 
the remote rural areas. 
 
The exclusion criteria 
Younger persons less than 18 years were excluded as they are not adults legally. Patients 
considered as “lost-to-follow-up patients” and those newly initiating therapy at the time of the 
study were also excluded from the study. Lost-to-follow-up patients were excluded because they 
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had incomplete prescription refill data and constituted a subset of the target population. Patients 
newly initiating therapy were less than 12 months on therapy and could not possibly have viral 
suppression, which is known to occur after six to ten months on therapy (Nachega et al., 2004; 
Pradier et al., 2001; Clay, 2005). The exclusion of these groups from the study means that 
findings of the current study are not generalizable to them. With adherence patterns likely to be 
different among these groups, other studies are recommended. 
 
The limitations highlighted above should not discourage the implementation of the 
recommendations of the current study by policy makers and the ART program implementers. 
However, it is very important that the implementation is done within the context of these 
limitations.   
 
5.8 Strengths of the study (contributions of the study to existing knowledge and practice) 
The current study has contributed to both knowledge and practice.  
a) Contribution to practice in combination anti-retroviral therapy in the FCT, Nigeria 
and sub-Saharan Africa 
Practice is defined as a way of doing something that is the usual or expected way in a particular 
organization or situation. Some findings of the current study may contribute to current practice in 
the area of combination anti-retroviral therapy (cART), particularly in the FCT and Nigeria. The 
most important contributions are listed below: 
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The identification of adherence barriers and facilitators  
This is the first study that described in a comprehensive way, the adherence level and its 
determinants in the FCT. Policy makers and the ART program implementers for the first time 
know the factors that constrain and promote adherence and can devise interventions to address 
them to promote adherence in the FCT and Nigeria. The recommendations and limitations of the 
study, which have been fully discussed, would help streamline the interventions and safe cost in 
the process. 
 
Switching of patients with suspected treatment failures 
The current study found that among the participants who claimed adherent to their regimens, 
12.2% women and 8.1% men, had viral load >3000 copies/ l
3  
despite being on therapy for at 
least 12 months (Table 4.2). According to the Nigerian treatment guideline, treatment failure is 
expected with these patients (FMOH, 2009). The World Health Organization (2009) and the 
Nigerian treatment guideline (FMOH, 2009) recommend the switching of patients with treatment 
failure to second line regimen. Thus, the finding of the current study might likely alert and drive 
the study centre to embark on the switching of these patients to the appropriate regimen. Other 
treatment centres might be encouraged by this and promote the same practice at their centres. 
 
Antiretroviral drugs can be tolerated 
The current study found that most participants did not suffer side effects from their drugs. 
Considering the fact that ARVs are seen as toxic drugs with serious fatalities, this is an 
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encouraging report that may boost confidence on the use of ARVs and consequently increase 
their usage. 
b) Contribution to existing knowledge in cART in the FCT, Nigeria and sub-Saharan 
Africa 
The WHO defines knowledge as the information, understanding and skills that are gained 
through education or experience (WHO, 2006a). Some findings in this study were consistent 
with findings in other adherence studies and as such, contribution to existing knowledge is made. 
 
Supobtimal adherence in sub-Saharan Africa 
Emerging studies are reporting high levels of adherence in sub-Saharan Africa (Nachega et al., 
2010). The finding of suboptimal adherence in the current study lent support to the concern 
raised by Gill et al that adherence rates in sub-Saharan Africa have been exergerated and true 
adherence rates remain unknown (Gill et al., 2005). The current study contributes to knowledge 
by questioning the way adherence has been measured by previous researchers in Africa. The 
reported high adherence levels are also questioned and it is insisted that adherence must be 
measured comprehensively in sub-Saharan Africa. 
 
Measuring adherence by self-report should be comprehensive  
One major finding of the current study that reflects independent thinking and originality and may 
contribute to existing knowledge in cART, is the finding that assessing adherence by self-report 
using only one criterion, e.g., doses missed or taken, is not comprehensive enough. The review 
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of literature showed that only one adherence study in sub-Saharan Africa has evaluated self-
reported adherence using different criteria (Jean-Baptiste, 2008). This is a significant 
contribution to existing knowledge considering the limited studies evaluating self-reported 
adherence using different criteria. 
 
 Self-report and prescription refill measures of adherence correlate with virologic suppression 
The current study found a positively statistically significant association between adherence and 
virologic suppression, consistent with findings in many studies (Bangsberg et al., 2000; Gifford, 
Bormann, Shively, Wright, Richman and Bozzette, 2000; Haubrich et al., 1999; Chesney et al., 
2000; Paterson et al., 2000; Arnsten et al., 2001). This clearly contributes to knowledge in this 
area. 
 
5.9 Summary 
The current study found a suboptimal adherence rate in the FCT. Significant findings that were 
positively statistically and significantly associated with adherence were: virologic suppression 
and age. Psycho-social factors were the major barriers and motivators of adherence to the ART, 
which added to the reflection that drug adherence is a human behavior dependent on psycho-
social attributes.   
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CHAPTER SIX 
CONCLUSIONS AND RECOMMENDATIONS 
6.1 Conclusions 
The current study described adherence to anti-retroviral therapy as well as analyzed the factors 
that might constrain (barriers) and motivate (facilitators) adherence among adults who were on 
highly active anti-retroviral therapy in the Federal Capital Territory, Abuja, Nigeria, from 2005 
to 2010.  
Data were collected from exit-interviews, prescription refill records and viral load tests from 
consented patients systematically sampled from the ART clinic of the University of Abuja 
Teaching and analysed. 
 
Suboptimal adherence (53.6%) with high virologic suppression (80.3%) was reported; age and 
viral load were positively, statistically and significantly associated with adherence to ART. 
Similarly, forgetfulness, being busy with work and traveling was common barriers to adherence 
to the ART, while the perception that health condition improved as well as the desire to live had 
the greatest potentials of influencing adherence to ART according to current study.  
 
The current study questioned the way adherence to ART has been measured using the self-
reporting measure in sub-Saharan Africa. It insists that adherence must be measured 
comprehensively. The failure to follow specific instruction on timing of taking medication was 
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the critical reason for suboptimal adherence to ART, which health providers and the participants 
must address. 
 
6.2 Recommendations for improving adherence to highly active anti-retroviral therapy 
The current study found several adherence determinants that have the potentials of influencing 
adherence to the ART. The major determinants were divided into psychosocial, health system 
and community factors and were ranked in order of priority for the ease of intervention. By this 
ranking, the psycho-social factors have the highest priority and the community factors, the least. 
It is suggested that as interventions are deployed, this order of ranking should be followed 
particularly, if limited resources will not allow a comprehensive intervention on all the factors. 
Future areas of research are also recommended as the current study could not address all the 
critical issues identified in this study. 
 
Psychosocial factors 
The suggestions for addressing the psychosocial factors are listed below: 
a) Strengthen quality in counselling: 
 Fully evaluate patients’ motivation for treatment before starting the ART 
 Perform proper opportunistic infection (OI) screening, adverse drug reaction (ADR) and 
adherence monitoring 
 Train staff, including other support staff, in communication skills and adherence 
counselling. 
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 Use modern technology, for instance  cellular telephones  
 Use external prompts to help remind patients to take their medications as scheduled. 
 
Health system factors 
b) Reduce transport costs to the clinics: 
 Provide patients with drugs for a longer period  and arrange for better laboratory services 
so patients will not have to return so frequently 
 Bring services closer to the patients, and use peripheral community-based health workers 
for drug distribution 
  Give direct economic support and/or initiate income-generating programs 
 
c) Reduce waiting times in clinics: 
 Arrange more efficient flow of patients between different providers and stations 
appointment schedule, 
 Split appointments into two half days, 
 Keep clinics open on  additional days, 
  Increase number of staff 
 Decentralize services to the communities 
d) Strengthen conditions for constant supply of the ARVs, OI drugs and laboratory 
services: 
 Assign responsibility for drug supply to one person who is supported by the management 
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  Support stable donor-ship and efforts to reduce costs for opportunistic infection 
medicines or make arrangements for completely free medicines 
 Stabilize delivery of laboratory material; clarify the question of responsibility when 
problems arise with equipment maintenance and service 
 Support the use of the pull system for drug distribution 
 Train health staff who are involved in drug requisition on inventory management with 
focus on how to maintain constant availability of drugs 
 Modern drug forecasting tools should be provided to enable health staff involve in drug 
management to accurately forecast the needed quantities of drugs 
 
e) Strengthen the stocking of high quality and efficacious ARVs and opportunity infection 
drugs (OIs): 
 Procure drugs from reputable drug manufacturers that have met both the World Health 
Organization and the local regulatory agency such as, the National Agency for Food and 
Drug Administration and Control (NAFDAC) pre-qualification standards on 
manufacturing. 
 ARVs should be stored at the manufacturers’ recommended temperatures to maintain 
their integrity. As temperatures in the FCT are higher than the recommended 25 degree 
Celsius, Air Conditioners, Fans and other cooling systems should be provided and room 
temperatures in the drug stores should constantly be monitored using wall thermometers.  
 
f) Strengthen the stocking of user friendly ARVs 
 Focus on stocking the fixed dose combinations ARVs which are user friendly 
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Community factors 
g) Strengthen community linkages: 
 Use relevant number of peripheral trained community-based health workers, preferably 
those with experience on living with HIV/AIDS 
 Collect information on patients’ health status and adherence, thus detecting defaulters, 
which is communicated by cell-phones back to the clinics 
 Use community-based health workers for support in a home-based model on nutritional 
matters and HIV/AIDS care. 
 
Future areas of research 
 Suboptimal adherence 
A suboptimal adherence was reported. The adherence model presently in use at the treatment 
centre does not seem to be effective. There is need to design an adherence model to address the 
poor adherence among the patients with confirmed treatment failure.  
 
Causation 
Analytical studies should be designed to evaluate the causes of poor adherence in the FCT. The 
cross sectional nature of this study did not allow this. 
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Months on therapy and side effects of drugs 
Majority of the participants in this study were on therapy for a longer duration and only a few of 
them experienced side effects from their medications. Does the length of time on the HAART 
medications completely eradicate the risks of side effects? Or is there a time frame when the side 
effects of the ARVs completely disappear? These questions need further investigations. 
 
Potential adherence determinants 
The study did not look into some of the potential socio-economic and psycho-social factors 
influencing adherence, such as income level (Kleeberger, Phair, Strathdee, Detels, Kingsley and 
Jacobson, 2001), housing (Duran et al., 2001), life event (Moatti, Carrieri, Spire, Gastaut, 
Cassuto and Moreau, 2000) and depression (Moatti, Carrieri, Spire, Gastaut, Cassuto and 
Moreau, 2000). Overall, various findings of the current and other studies on the impact of 
demographic and psycho-social variables call for the need to seriously attend to these potential 
factors in adherence to anti-retroviral therapy. 
 
In conclusion, ARV adherence rate in the FCT is low with high virologic suppression. To help 
patients manage a life long adherence to the ART, emphasis on the correct use of medication is 
necessary. Psychosocial factors contrain and motivate adherence to ART; they must be addressed 
in order to improve adherence to ART in the Federal Capital Territory, Abuja, Nigeria. 
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APPENDIX 4: Participant Information Sheet (English) 
 
 
                                          
     UNIVERSITY OF THE WESTERN CAPE 
                  School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
November 2009 
 
Dear Participant 
 
Thank you for your willingness to be informed about this study. What follows is an explanation 
of the study and your potential involvement. This study is being conducted for a mini-thesis as 
part of the requirements for a Masters in Public Health degree which I am completing at the 
University of the Western Cape. You are free to ask me anything that may be unclear or that you 
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do not understand. My contact details and those of my supervisor can be found at the end of this 
memo. 
 
TITLE OF RESEARCH 
Adherence to Antiretroviral Therapy in the Federal Capital Territory, Abuja, Nigeria  
  
PURPOSE OF THE STUDY 
This study is set out to estimate the level of adherence to antiretroviral medicines and other 
medicines use in the management of HIV/AIDS. The factors that may hinder adult people living 
with HIV/AIDS from taking their HIV medicines as recommended for them by the health worker 
will also be looked into. The result of the study will provide information on how to improve 
adherence and reduce the barriers to adherence so that people living with HIV/AIDS can take 
their medicines properly and reduce the problems cause by HIV/AIDS. 
 
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT 
The study will include interviews with adult people living with HIV/AIDS. Questions about your 
experiences/views with HIV  medicines will be asked. In particular, you will be asked to say how 
you have been taking your HIV/AIDS medicines and the challenges you have been having with 
taking these drugs and other drugs you have been given. Participants will also be requested to go 
to the laboratory to do a viral load test so as to know the level of the viruses in their body. 
 
CONFIDENTIALITY 
Your name will be kept confidential at all times and I shall keep all records of your participation, 
including a signed consent form which I will need from you should you agree to participate in 
the study, locked away at all times and will be destroyed after the study is completed. 
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VOLUNTARY PARTICIPATION AND WITHDRAWAL 
Your participation in this study is entirely up to you as you may not participate if you so decide. 
However, if you choose to participate, you may withdraw at anytime or may choose not to 
answer particular questions that may be asked. Please feel free to inform me if there is anything 
that you would prefer not to discuss. If you decide not to participate or withdraw from the 
research at any point, please be assured that you will not be adversely affected in any way. 
 
BENEFITS AND COSTS 
You may not get any immediate benefit from this study. However, you will know the level of 
viruses in your body which the doctors may need to treat your health problems better. It is also  
hoped that the information and the suggestions gathered from this study will act as a guide to 
inform policy-making by the relevant authorities and the overall benefit of all concerned. The 
only costs that accrue to you for participating in this study is the time you spend in the interviews 
and the small amount of blood you will provide for the viral load test. 
 
INFORMED CONSENT 
Your signed consent to participate in this study is required before I proceed to interview you. I 
have included the consent form with this information sheet so that you will be able to review the 
consent form and then decide whether you would like to participate in this study or not. 
 
QUESTIONS 
Should you have further questions or wish to know more, I can be contacted as follows: 
 
Avong Yohanna Kambai 
Student Number: 2831679 
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Mobile phone: 234 8033159205 
E-mail: yavong@gmail.com 
Office telephone: 234 8033159205 
 
I am accountable to my supervisor, Dr. Brian van Wyk at The University of the Western Cape, 
South Africa.  
Dr van Wyk’s contact details are: 
E-mail: bvanwyk@uwc.ac.za; Tel No. +27828049055 while  
 
Dr. Brian could also be contacted at: 
The School of Public Health 
Fax: +27 21 959 2872  
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APPENDIX 5: Participant Information Sheet (Hausa) 
 
 
                                          
     UNIVERSITY OF THE WESTERN CAPE 
                  School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
November 2009 
 
Ya me shiga wannan aikin 
 
Ina maka/miki godiya domin ka/kin yarda na yi maka/miki bayani game da wannan aikin 
bincike. Zan yi maka/miki bayani akan yadda aikin zai kasance da abubuwan da zaka/zaki yi. Ina 
yin wannan aikin bincike ne domin yana cikin aiyukan da ya kamata nayi a karatuna na ilimin 
kiwon lafiyar jama’a a Jami‘an Western Cape. Kana/kina iya yi mani tambaya akan abun da 
baka/baki gane ba. Akwai lambar waya na da na malamina me duba aikin a karshen wannan 
takardan. 
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SUNAN BINCIKEN 
Yadda mutane ke mannewa wa shan magungunar kwayar cutar HIV, wato magungunar ARV a 
birnin Abuja a Najeriya  
  
DALILIN YIN WANNAN BINCIKEN 
Wannan aikin bincike zai duba yanayin da mutane ke mannewa wa shan magungunar ARV tare 
da sauran magunguna domin kula da lafiyarsu ko da suna dauke da kwayar cutar HIV. Zamu 
kuma duba dalilan da kan iya hana manyan mutane masu dauke da kwayar cutar HIV daga shan 
magungunar yadda masu aikin asibiti suka  tsara musu. Sakamakon wannan aikin zai taimaka wa 
mutane masu dauke da kwayar cutar HIV su samu shan magungunarsu yadda ya kamata, ya 
kuma rage matsalolin da sukan fuskanta. 
 
BAYANI AKAN YADDA AIKIN ZAI KASANCE DA ABUWAN DA ZAKA/ZAKI YI 
Za’a tattauna tare da manyan mutane masu dauke da kwayar cutar HIV. Za’a yi maka/miki 
tambayoyi akan yadda kake/kike shan magungunarka/ki da ra’ayoyinka/ki game da magungunar 
ARV. Za’a yi maka/miki tambaya musamma akan yadda kake/kike shan magunguna da 
matsalolin da kake/kike fuskanta wajen shan magungunar ARV da sauran magunguna. Za’a 
nema wanda suka shiga wannan aikin bincike su je dakin gwaji a auna jininsu domin a gane 
yawan kwayoyin cutar da suke dauke da shi. 
 
SIRRI 
Zan addana sunanka/ki a sirrance a ko wanne lokaci tare da takarda bada yardanka/ki wanda 
zaka/zaki sa hannu akai idan ka/kin yarda ka/ki shiga wannan bincike, zamu addana wadannan 
tarkardu a kulle a kowane lokaci kuma za’a kona su bayan an gama wannan aikin. 
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SHIGA KO FITA DAGA WANNAN BINCIKE 
Shiganka/ki cikin wannan bincike ba tilas bane ba, zaka/zaki shiga ne domin ka/kin ga damar 
shiga ne. Idan kuma ka/kin shiga cikin wannan binciken zaka/zaki iya fita a kowanne lokaci da 
ka/kika ga dama, kuma zaka/zaki iya kin amsa tambaya wanda baka/baki ga damar amsawa ba. 
Zaka/zaki iya mun bayani akan irin abubuwan da baza ka/ki so ka amsawa ba. Idan baka/baki so 
ka/ki shiga wannan binciken ba, ko kuma ka/kin fita bayan ka/kin shiga babu wata hukunci da 
za’a yi maka/miki. 
 
AMFANI DA KUDIN WANNAN BINCIKEN 
Zai iya yuwa baza ka/ki samu amfanin shiga wannan bincike ba kai tsaye. Amma dai zaka/zaki 
samu sani akan yawan kwayoyin cuta dake cikin jikinka/ki wanda zai taimakawa likitoci su gane 
yadda zasu kula da kai/ke a wata hanya mafi kyau. Kuma ana fatan cewa bayanen da zamu samu 
a wannan aikin bincike zai taimaka wajen gyara manufan shugabanne domin sauran mutane. 
Abun da zamu tambaya daga gare ka/ki shine lokacin da zaka/zaki bamu da dan kankanin jini 
wanda zamu diba domin gwajin kwayoyin cuta. 
 
SAMUN CIKAKKEN BAYANI DA BADA YARDA 
Sai na samu izinika/ki da sa hannunka/ki a takardan bada yarda kafin na fara tattaunawa tare da 
kai/ke game da wannan binciken. Takardan bada yarda na hade da wannan takardan, zaka/zaki 
samu ka/ki karanta shi ka/ki san ko kana/kina son ka/ki shiga cikin wannan binciken. 
 
TAMBAYOYI 
Idan kana/kina da wasu tambayoyi ko kuma kana/kina son ka/ki kara sani na, zaka/zaki iya samu 
na a: 
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Avong Yohanna Kambai 
Lambar makaranta: 2831679 
Lambar wayar hannu: 234 8033159205 
Adireshi yanar gizo: yavong@gmail.com 
Lambar ofis: 234 8033159205 
 
Zaka/zaki kuma iya samun malami mai duba aiki na, Dr. Brian van Wyk, a kasar South Africa.  
Adireshin Dr van Wyk’s shine: 
Adireshi yanar gizo: bvanwyk@uwc.ac.za; Tel No. +27828049055  
 
Za’a kuma iya samun Dr. Brian  a: 
The School of Public Health 
Fax: +27 21 959 2872  
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APPENDIX 6 Informed Consent Form 
                                                              
 
    UNIVERSITY OF THE WESTERN CAPE 
                    School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
RECORD OF INFORMED CONSENT TO CONDUCT INTERVIEW 
 
Thank you for agreeing to participate in this study. 
 
As part of my Masters in Public Health, I am required to carry out an interview to obtain the 
necessary information needed for my thesis. I will be focusing on the adherence to antiretroviral 
therapy in the Federal Capital Territory, Abuja. 
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This research is intended to look at the level people living with HIV/AIDS (PLWHA) are using 
HIV medicines and other drugs as well as look at the factors that hinder people from using their 
medicines as recommended by the health worker. The level to which these factors hinder proper 
usage of HIV medicines and other medicines and the relationship between the factors and 
adherence will also be looked at. 
 
As has been mentioned in the Participant Information Sheet, acceptance to participate in this 
study is your choice and is completely voluntary. You may choose to withdraw from the study or 
refuse to participate in the study at any time. Such refusal to participate will not result to your 
loss of any benefit or to any penalty. You may also choose not to answer particular questions that 
may be asked. If there is anything that you do not feel comfortable to discuss, feel free to say so. 
 
At all times, I will keep the source of the information confidential and refer to you or your words 
by a pseudonym or invented name which I would like you to choose. I shall keep any other 
records of your participation locked away and destroy them after the data has been collected. 
 
In order for us to start, you are required to sign a consent form below as a sign of your approval.  
 
I have read the information about this research study on the Participant Information Sheet, or it 
has been read to me. I have had the opportunity to ask questions and any questions that I have 
asked has been answered to my satisfaction. 
 
I hereby consent to participate in this study.   
 
My signature attests to my acceptance to participate in the study. 
 
 
 
 
 xv | P a g e  
 
            
Name of Participant…………………………………. 
 
 
Participant signature …………………………………Consent    Date…………………………… 
 
 
Researcher’s Name…………………………………….                                                                                             
 
Researcher Signature………………………………….Date 
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APPENDIX 7 Informed Consent Form (Hausa) 
                                                              
 
    UNIVERSITY OF THE WESTERN CAPE 
                    School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
TAKARDAN BADA YARDA A SHIGA AIKIN BINCIKE 
 
Ina maka/miki godiya da ka/kika yarda ka shiga wannan aikin bincike. 
 
Ina yin wannan aikin bincike ne domin yana cikin aiyukan da zan yi a karatuna na ilimin kiwon 
lafiyar jama’a a babbar jami’a. Zan yi bincike ne akan yadda mutane ke manne wa shan 
magungunar kwayar cuta me karya garkuwar jiki (HIV), wato magungunar ARV a birnin Abuja. 
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Wannan binciken zai duba yanayin da mutane masu dauke da kwayar cuta me karya garkuwar 
jiki ke amfani da magungunar ARV da sauran magunguna, kuma zai duba ire-iren abubuwan da 
zasu iya hana su amfani da magungunar kamar yadda masu aikin asibiti suka tsara musu. Ana 
son a kuma gane tsananin wannan rashin amfani da magungunan da kuma dangantakansa da 
mannewa wa shan magunguna. 
 
Kamar yadda aka bayyana a takardan bada bayani shiga wannan bincike ba tilas bane ba kuma 
kana/kina iya fita daga cikin binciken a kowanne lokacin da ka/kika ga dama. Ba za’a yi 
maka/maki wata hukunci ba domin ka ki ka shiga wannan binciken ba ko kuma domin ka/kin fita 
daga cikinsa ba. Kana kuma da dammar kin amsa tambayoyin da basu yi maka ba, zaka/zaki iya 
gaya mana irin wadannan tambayoyin. 
 
Zan addana takardun aikin nan da kyau a sirrance kuma zan yi amfani da wata suna daban wanda 
zaka/zaki zaba yanzu. Zan addana takardun aikin nan a kulle kuma zan kona su bayan an gama 
wannan aikin binciken. 
 
Kafin mu fara wannan aikin zan nemi ka/ki saka hannu a karshen wannan takardan domin nuna 
bada yardanka/ki. 
 
Na karanta bayanen game da wannan aikin binciken akan Tarkardan Bayani, ko kuma an karanta 
mun wannan bayani. An kuma bani dammar yin tambayoyi kuma an amsa mani tambayoyin a 
kamar yadda nake so. 
 
Yanzu na yarda na bada izini na shiga wannan aikin binciken.   
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Sa hannuna a wannan takardan ya shaida yarda na na shiga wannan aikin binciken. 
            
Sunan me shiga binciken ……………………………….…………………………………. 
 
 
Sa hannun me shiga binciken ……….………………………………… Bada yarda 
Ranar wata …………………………… 
 
 
Sunan me aikin bincike …………………………………………………………………….                                                                                             
 
Sa hannun me aikin bincike …………………………………. Ranar wata ………………. 
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APPENDIX 8 Viral Load Order and Results Form 
 
 
Viral Load Order and Results Form 
 
 
 
 
Facility Name:   1. Collection Date (dd/mm/yyyy) /                 /20 
 
2. Name    
 Surname  Other Names 
3. ID                4. Hospital No.  
 State  Facility No.  Serial Enrollment No.  
 5. Sex  F  M  6. Age    years If  < 5 years    months  7. Lab Reg. No.  
            
 
ORDERS RESULTS INDICATION FOR THE  VIRAL LOAD TEST: 
    
 Viral Load         copies/ml  Prior ART treatment, now on ART ≥ 4 months (child or adult) 
 Poor adherence history, now adherent ≥ 4 months (child or adult) 
 Immunological failure (child or adult) 
 Clinical failure (child or adult) 
 Child infected in spite of PMTCT 
 Child breast fed with Mom on HAART 
 Other ______________________________ 
 Research ___________________________ (Indicate Study) 
 
 Take Repository Sample  
 
 Drug resistance testing (Genotyping)  
      Approved by _________________________  
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Ordered by:      
 Clinician  Name  Signature  Date (dd/mm/yyyy) 
Reported by:      
 Print Name  Signature  Date (dd/mm/yyyy) 
Checked by:      
 Print Name  Signature  Date (dd/mm/yyyy) 
In folder by:      
 Print Name  Signature  Date (dd/mm/yyyy) 
 
     PMM-LOV.3.02.02062009 
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APPENDIX 9 Standard Operating Procedure forViral Load Sample Collection, 
Processing, Storage and Shipment  
 
 
 
 
BENCH TOP SOP 
FOR 
 VIRAL LOAD SAMPLE COLLECTION, PROCESSING 
STORAGE AND SHIPMENT 
 
Warnings and Precautions: All the procedures performed here must be done with standard, 
universal biosafety precautions. All required materials and equipment should be available prior 
to collection! 
 
Specimen 
The test is for use with human plasma (EDTA) specimens only. 
Specimen Collection; 
1. Confirm patients’ identification prior to collection, 
2. Label the EDTA vacutainer (tubes) with Clients identifiers, date and time of blood draw, 
3. Wear powder free gloves for the blood draw, 
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4. Draw 10mls of blood into (10 ml volume) EDTA tube OR use two 5ml volume EDTA,  
5. Allow blood flow to stop by itself, 
6. Mix the blood by inverting the tube 15times, 
7. Pack samples into tube rack and place in Specimen transport box for transfer to the Lab 
8. Change gloves before and after blood draw from each Patient, 
9. Blood tubes must not be opened until samples are ready to be processed in the laboratory. 
10. Whole blood must be transported to the Lab at 2-25oc and processed within 6 hours of 
collection . 
 
Specimen Handling/Processing; 
1. Each Specimen and batch should be accompanied by appropriate documentation 
2. Separate plasma from whole blood within 6 hours of collection. 
3. Centrifuge sample at 800-1600x g for 20minutes at room temperature. 
4. Transfer plasma to a sterile 2 ml polypropylene screw capped tube  
5. Aliquot 1ml of sample each into three, sterile 2ml cryovials. 
 
Specimen storage; 
1. Plasma may be stored at 2 - 8 0C for up to 5 days in cryovials or frozen at –70 0C in 1000 
ul (1ml) amounts in sterile screw cap tubes. 
2. Pack vials into labeled freezer storage boxes and store. Note the position of each sample 
and document on a storage spreadsheet. 
3. Create a freezer storage box map indicating position of each sample. 
 
Specimen Transport/Shipment to PCR reference Labs 
1. Plasma may be transported at 2 - 8 0C or frozen.  
2. Ensure that samples are properly sealed and there is no leakage. 
3. Pack samples into freezer storage boxes in an orderly fashion (serially or numerically) 
4. Generate a list of the samples to match their positions in the freezer storage box 
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5. Prepare the transport box; line the bottom and sides  with ice packs  
6. Pack samples (i.e. those in the freezer boxes) into the transport box for shipment. 
7. Each specimen and batch must be accompanied by appropriate documentation. 
8. Ship specimen to PCR testing centre  
 
Specimen Reception/rejection; 
1. Check sample labels, integrity and suitability. 
2. Match samples with the accompanying document and request form 
3. Document contents, check contents against accompanying manifesto. 
4. Note date and time of receipt. 
5. Reject any sample with questionable integrity, samples with missing or mis-matched 
identifiers. 
6. A feedback communication should be sent to where the samples came from.   
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APPENDIX 10 Standard Operating Procedure for Blood Collection 
 
BLOOD COLLECTION MATERIALS 
PPE 
•Disposable powder free latex gloves  
•Lab coats 
•Goggles 
 
COLLECTION DEVICE 
 Alcohol Wipes  
 Vacutainer Needles                                                                     
 Vacutainer/ Blood Collection Tubes-EDTA 
 Vacutainer holder 
 Tourniquet (Elastic Band) 
 Plasters (optional) 
 Biohazard Waste Container 
 Markers  
 Gauze or cotton wool 
 Test Tube Racks  
 Transport boxes  
 
STORAGE DEVICES 
 2ml polypropylene screw-cap tubes 
 Freezer storage boxes  
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DOCUMENTS 
 Patient Forms 
 Transfer Documents 
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APPENDIX 11 Standard Operating Procedure for Viral Load Estimation Using Amplicor 
HIV-1 Monitor Test, Version 1.5 
 
 
 
 
 
Bench Top Reference 
FOR 
VIRAL LOAD ESTIMATION USING AMPLICOR HIV-1 
MONITOR TEST, VERSION 1.5 
 
PCR REAGENT PREPARATION AREA 1 
 
Warnings and Precautions: Always wear new gloves and lab coat when proceeding to the next 
area. All Amplification reagents must be at room temperature (RT)! 
 
REAGENT PREPARATION- (MASTER MIX-AMPLIFICATION REAGENT) 
 
1. Determine the number of samples and controls to be tested. 
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2. Place the tray on the MicroAmp base, 
3. Assemble the appropriate number of MicroAmp tubes in the tray and place retainer on 
the tray and tubes. 
4. Prepare working Master Mix by adding 100ul of Mn2+ solution to 1 vial of Master Mix.  
5. Mix well by inverting 10-15 times. Pink color denotes presence of Mn2+ in the Master 
mix. 
No. Of Test 12 
MMX 1Vial (700ul) 
Mn
2+
 100ul 
 
6. Pipette 50ul of Working Master Mix into each Micro Amp tube. Visually inspect tubes to 
ensure that Master Mix has been added. (Place MicroAmp tray in resealable plastic bag 
and place sealed bag in the refrigerator at 2-8oC in AREA 2 until ready to add samples).  
 
NOTE: AMPLIFICATION MUST BEGIN WITHIN 4 HOURS OF PREPARATION OF 
WORKING MASTER MIX 
 
NOTE: ALL VORTEXING SHOULD BE DONE FOR AT LEAST 3 SECONDS UNLESS 
OTHERWISE NOTED. 
 
PCR SPECIMEN PREPARATION AREA 2 
 
REAGENT PREPARATION-(EXTRACTION) 
 Prepare 70% ethanol. For 12 tests, mix 11.0ml of 95% ethanol with 4.0ml deionized 
water (Make fresh daily). 
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 Visually inspect Lysis Reagent to make sure that it is homogenous and there is no 
precipitate present. (The lysis reagent should be placed in an incubator at 37
0c 
for at east 
30 minutes prior to reconstitution) 
 Vortex QS well. Prepare working lysis Reagent by adding 100ulof QS to one vial of lysis 
Reagent. Vortex thoroughly; Note: working Lysis Reagent must be used within 4 hours 
of preparation.  
 
SAMPLE PREPARATION- (Bring out samples to thaw about 30mins before   
 assay) 
1. Complete “Tray Map” for sample and control identifications. 
2. Determine the correct number of 2.0ml Sarstedt tubes needed for samples and controls. 
Label and place an orientation mark on each tube. 
3. Add 600ul of thoroughly mixed working Lysis Reagent to each Sample and control tube. 
4. For the controls (negative, low and High positive controls), add 200ul of Normal Human 
Plasma (NHP) to the appropriately labelled tubes containing the Working Lysis Reagent 
and vortex immediately.  
5. Vortex controls and add 50ul of the appropriate controls to the tubes containing NHP and 
working Lysis Solution. Vortex immediately. 
6. Vortex thawed patients’ samples. Add 200ul of patients’ samples to the appropriately 
labelled tubes containing Working Lysis Reagent and vortex immediately.  
7. Incubate all tubes at room temperature for 10mins(could exceed 10mins, start timer after 
last tube) 
8. Add 800ul of 100% Isopropanol to each tube and vortex immediately. 
9. Position the tubes in the centrifuge so that the orientation marks are facing outward. 
Centrifuge tubes for 15minutes at ≥12, 500x g at room temperature. 
10. Using a fresh fine tip transfer pipette for each sample, carefully aspirate and discard the 
supernatant without disturbing the pellet. (sometimes the pellet will not be seen). 
11.  Add 1 ml of 70% ethanol to each tube and vortex. Centrifuge for 5 minutes at ≥12, 500x 
g at room temperature. 
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12. Using a fresh fine tip transfer pipette for each sample, carefully aspirate and discard the 
supernatant without disturbing the pellet. 
13. Centrifuge for 5 minutes at ≥12, 500x g at room temperature (to spin down excess 
ethanol), use a fresh fine tip transfer pipette for each sample, aspirate and discard the 
supernatant. 
14. Resuspend the pellet in 400ul of Specimen diluent. Vortex each sample for 10 seconds. 
(Scratch each tube vigorously to mix). If the resuspended sample will not be amplified 
within 2 hours of preparation, store at –20oC or colder for up to 1 week. 
15. Remove MicroAmp Tray from the refrigerator, Pipette 50ul of each extracted sample or 
control into the appropriate Micro Amp tube containing the Working master Mix. 
16. Cap tubes tightly using Capping tool. 
17. Move capped tray to AREA 3 for amplification and detection. 
     
 
PCR AMPLIFICATION AND DETECTION AREA 3 
Warnings and Precautions: Always wear new gloves and lab coat when proceeding to the next 
area. All Amplification reagents must be at room temperature (RT)! 
 
Amplification and Detection Area- (Put on the Thermocycler for about 2 minutes to warm up 
before loading the tray into it)  
 
1. Place sample tray into the thermocycler sample block. 
2. PROGRAM The Gene Amp™ PCR System as        
     follows (This is already programmed as method 5 in the  
     Thermocycler): 
 HOLD Program: 2 min @ 50oC 
 HOLD Program: 30 min @ 60 oC 
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 Cycle Program (8 cycles): 10 sec @ 95 oC, 10 sec @ 52 oC, 10 sec @ 72 oC 
 Cycle Program (23 cycles): 10 sec @ 90 oC, 10 sec @ 55 oC, 10 sec @ 72 oC 
 HOLD Program: 15 min @72 oC 
  
POST AMPLIFICATION; 
 Remove the MicroAmp tray from the Thermal Cycler and place into the tray base. 
Carefully remove all caps from the tubes avoiding creating aerosols of the amplification 
reaction mixtures.   
 Immediately add 100 ul of Denaturation Solution (1) each reaction tube using a 
multichannel pipettor with plugged tips.  
 Mix by pipetting up and down 5 times.   
Note: Do not hold denatured Amplicons at RT for more than 2 hours. If detection will not 
be performed within 2 hours recap the tubes and store the denatured amplification 
reaction mixtures at 2 – 8oC for up to one week.  
      
 
DETECTION  
1. Remove Microwell plate (MWP) from the foil pouch. 
2. Pipette 100ul of Hybridization solution into each well of the MWP (Impact pipettor 
program2) 
3. Using plugged tips and a multichannel pipettor; add 25ul of the denatured amplicons 
from the first row (Row A) of the MicroAmp tray to the first row (Row A) of the MWP. 
Mix well by pipetting up and down 5 times, and then transfer 25ul to the next row of 
wells (Impact Pipettor Program 3). 
4. Repeat this procedure 4 more times through Row F so as to generate 5; five fold dilutions 
(1:5, 1:25,1:625, 1:3125). Remember to remove and discard 25ul from the last row of 
wells after mixing. 
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5. Add 25ul of dentured amplicons from the first row (Row A) of the Micro Amp tray to the 
first green trimmed row (Row G) on the MWP. Mix well by pipetting up and down 5 
times, and then transfer 25ul to the next row of wells on the MWP (Impact Pipettor 
Program 3). After mixing in Row H, remove and discard 25ul of this mixture. 
6. Cover the MWP with the plastic notched lid and incubate for 1 hour at 37oC. 
7. Prepare the working Wash Solution by adding 1 part of 10X Wash Concentrate to 9 parts 
of distilled or deionised water. Mix well. 
8. Wash the MWP 5 times with Working Wash Solution. 
9. Add 100ul of AV-HRP Conjugate Solution to each well (Impact Pipettor Program 2). 
Cover plate and incubate for 15 minutes at 37 oC. 
10. After the 15 minutes incubation, wash the MWP 5 times with working Wash Solution.  
11. Prepare Working Substrate by measuring and mixing 12.0ml of substrate A and 3.0ml of 
Substrate B. Protect from exposure to light. 
12. Add 100ul of Working Substrate to each well of the MWP (Impact Pipettor Program 2). 
Allow color to develop in the dark for 10 minutes at room temperature. 
13. Add 100ul of Stop Solution to each well of the MWP (Impact Pipettor Program 2) 
14. Measure the optical density at 450nm within 10 minutes of adding Stop Solution. Using 
these absorbance values, do the appropriate calculation. 
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APPENDIX 12: Exit Interview Questionnaire 
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